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  Epidemiological studies as well as controlled animal studies have associated exposure to 
arsenic through drinking water with the development of atherosclerosis. In this study, we 
have shown for the first time that low and environmentally relevant concentrations of 
arsenic accelerate atherogenesis. The objective of this study was to elucidate the 
mechanisms of arsenic-induced atherosclerosis by (1) characterizing the time- and 
concentration-dependent effects of sodium arsenite [As(III)] on the development of 
atherosclerosis in ApoE-/- /LDLr-/- mice, (2) determining whether As(III)-induced 
peroxynitrite activates protein kinase C (PKC) isotypes, α and β, in human aortic 
endothelial cells (HAECs) and (3) determining the effects of activation of PKC isotypes, 
α and β, on the endothelial barrier. Accordingly, exposure of ApoE-/- /LDLr-/- mice to 
As(III) in drinking water showed an increasing trend in atherosclerotic plaque formation 
in as early as 5 weeks within the innominate arteries. Most remarkable was the evidence 
that environmentally relevant concentrations of As(III) resulted in significant increase in 
plaque formation. Initiation of atherosclerosis results from activation/dysfunction of the 
vascular endothelium that maintains a semipermeable barrier between the blood and 
vessel wall. To elucidate the mechanism of arsenic-induced atherosclerosis, we analyzed 
the effect of As(III) on the endothelial monolayer integrity. Endothelial barrier is 
maintained by proteins of the adherens junction (AJ) such as vascular endothelial 
cadherin (VE-cadherin) and β-catenin, and their association with the actin cytoskeleton. 
Treatment of HAECs with As(III) resulted in reorganization of actin filaments into stress 
fibers and non-uniform VE-cadherin and β-catenin staining at cell-cell junctions. 
Intercellular gaps were observed with a measured increase in endothelial permeability. In 
addition, an increase in tyrosine phosphorylation (PY) of β-catenin was observed. These 
effects were mediated through As(III)-induced activation of PKCα without peroxynitrite 
formation. No change in PKCβ levels was detected with As(III) treatment. Inhibition of 
PKCα restored VE-cadherin and β-catenin staining at cell-cell junctions and abolished the 
formation of intercellular gaps and stress fibers. Endothelial permeability and PY of β-
catenin were also reduced to basal levels. These results demonstrate that As(III) induced 
activation of PKCα causes PY of β-catenin and formation of stress fibers. PY of β-
catenin causes weakening of the AJ and this in association with the contractile force 
generated by stress fibers results in gap formation and increased endothelial permeability. 
This could potentially accelerate the development of atherosclerosis by increasing the 
accumulation of oxidized low density lipoproteins and monocytes into the neo-intima of 
the blood vessel. The findings in this study demonstrate that arsenic disrupts the 
endothelial monolayer by activation of PKC signaling. Damage to the endothelium 
plausibly accelerates the process of atherosclerosis at an early stage as evidenced by the 
increase in atherosclerotic plaques in the ApoE-/- /LDLr-/- mouse model. 
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Chapter 1 
Introduction 
 
1.1 Rationale 
Millions of people worldwide are exposed to arsenic through drinking water that 
has been associated with the development of cardiovascular diseases such as carotid 
atherosclerosis, ischemic heart disease and hypertension. Atherosclerosis is the 
fundamental cause of major cardiovascular diseases including ischemic heart disease, 
myocardial infarction and stroke. The focus of our laboratory has been to elucidate the 
mechanisms of arsenic-induced cardiovascular disease. The objective of this study was to 
determine the effects of arsenic on endothelial cell biology and the development of 
atherosclerosis. The in vivo effects of environmentally relevant concentrations of arsenic 
in atherogenesis were analyzed using the ApoE-/- /LDLr-/- mouse, which is a well-
established model of human atherosclerosis. The in vitro studies focused on determining 
the mechanism of arsenic-induced atherosclerosis by using human aortic endothelial 
cells. The research presented here lends a valuable contribution towards understanding 
the role of arsenic in cardiovascular toxicity and will aid in developing future treatment 
and prevention strategies. 
Specific Aim 1: Characterize the time- and concentration-dependent effects of As(III) on 
the initiation and progression of atherosclerosis in ApoE-/- /LDLr-/- atherosclerotic 
mouse model. 
Specific Aim 2: Determine the effects of As(III)-induced peroxynitrite on the activation 
of calcium-dependent cPKC isotypes, α and β, in human aortic endothelial cells. 
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Specific Aim 3: Determine whether activation of the cPKC isotypes, α and β, by As(III) 
is involved in endothelial barrier disruption. 
 
1.2 Cardiovascular Disease 
1.2.1 Statistics 
Cardiovascular disease (CVD) is the number one killer in the United States as 
well as developed Western countries. According to current estimates from the American 
Heart Association (Heart Disease and Stroke Statistics, 2007 update), about 80 million 
Americans have one or more types of CVD. The percentage breakdown of deaths from 
CVD is coronary heart disease (52%), stroke (17%), heart failure (7%), high blood 
pressure (6%), disease of arteries (4%), congenital cardiovascular defects (0.5%), 
rheumatic heart disease (0.4%) and other (13%). Atherosclerosis is the underlying cause 
of major clinical cardiovascular events. 
 
1.2.2 Risk Factors 
The American Heart Association has identified several risk factors for CVD based 
on extensive clinical and statistical studies. Some of the risk factors can be controlled 
through adequate lifestyle changes and/or use of medication, whereas others cannot be 
controlled. The controllable risk factors include cigarette smoking, high blood pressure, 
high blood cholesterol, diabetes mellitus, physical inactivity and obesity. The 
uncontrollable risk factors include increasing age, gender and heredity. Other risk factors 
have been associated with CVD, but their significance and prevalence are yet to be 
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confirmed. These factors are known as ‘contributing risk factors’ and include stress and 
excessive alcohol intake.  
 
1.2.3 Atherosclerosis 
Atherosclerosis is a complex, progressive and multifactorial disease characterized 
by deposition of lipid and fibrous elements in the subendothelial space. It is the 
underlying cause of serious clinical manifestations such as ischemic heart disease, 
myocardial infarction and stroke.  
 The normal large artery consists of three layers; the intima, media and adventitia 
(Fig. 1). The intima, the innermost layer, consists of extracellular connective tissue 
matrix, primarily collagen and proteoglycans. The intima is bounded by the endothelial 
monolayer on luminal side and elastic lamina on the peripheral side. The media, the 
middle layer, consists of smooth muscle cells. The adventitia is the outermost layer and 
consists of connective tissue with interspersed fibroblast and smooth muscle cells (Lusis, 
2000). An initiating event in the development of an atherosclerotic lesion or fatty streak 
is the accumulation of oxidized low density lipoproteins (oxLDLs) into the intima of 
blood vessel. The oxLDLs stimulate the overlying endothelial cells to express cell 
adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and 
intercellular cell adhesion molecule-1 (ICAM-1), proinflammatory cytokines such as 
interleukin-1 (IL-1) and IL-6, and chemokines such as monocyte chemottractant protein-
1 (MCP-1) and IL-8 (Tedgui and Mallat, 2006) (Fig. 2). The VCAM-1 expressed by 
endothelial cells play a major role in transmigration of monocytes from the blood into the 
intima (Cybulsky et al., 2001, Nakashima et al., 1998) along with MCP-1 (Libby, 2002). 
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Once inside the intima, the monocytes differentiate into macrophages and internalize 
oxLDLs resulting in the formation of lipid laden foam cells. The activated macrophages 
further secrete proinflammatory cytokines such as tumor necrosis factor α (TNFα), IL-1, 
and IL-6, and chemokines such as IL-8 and MCP-1 that in turn can activate endothelial 
cells, smooth muscle cells (SMC) and resident macrophages leading to a self-
perpetuating inflammatory process (Tedgui and Mallat, 2006). 
 4
 
 
 
Fig. 1. Structure of a normal large artery 
Reprinted by permission from Macmillan Publishers Ltd: Nature; Lusis, 2000, © 2000 
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Fig. 2. Development of atherosclerotic lesion. 
Reprinted by permission from Macmillan Publishers Ltd: Nature; Libby, 2002, © 2002 
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 Accordingly, it has been observed that stimulation of endothelial cells from 
different vascular beds such as human aortic endothelial cells (HAEC), human coronary 
artery endothelial cells (HCAEC) or human heart microvascular endothelial cells 
(HHMEC) with proinflammatory cytokines, TNFα and IL-1β, upregulates the expression 
of VCAM-1 (McDouall et al., 2001). Co-culture experiments of endothelial cells with 
human peripheral blood mononuclear cells (PBMC) revealed increased binding of PBMC 
to TNFα stimulated endothelial cells, implying that the increased expression of VCAM-1 
may increase adhesion to the endothelium and transmigration of monocytes into the 
blood vessel intima during inflammatory conditions (McDouall et al., 2001). Consistent 
with this, using an en face imaging technique, Nakashima et al. (1998) reported that in 
apolipoprotein E deficient (ApoE-/-) mice, VCAM-1 is upregulated at the lesion-prone 
sites by hypercholesterolemia. The authors concluded that VCAM-1 expression is an 
early event that precedes fatty streak formation and may play a critical role in monocyte 
recruitment from the blood. Also, elevated levels of soluble VCAM-1 have been detected 
in the plasma of patients with coronary heart disease and myocardial infarction compared 
to healthy subjects (Zeitler et al., 1997). 
 During the progression of an atherosclerotic lesion there is accumulation of 
excessive lipid, multiplying SMCs and SMC-derived extracellular matrix, especially 
collagen. The developing plaque consists of a core, fibrous cap covering the plaque and 
the shoulder region (Lusis, 2000). Composition of the plaque determines its stability. 
Vulnerable plaques generally have thin fibrous cap, decreased collagen content and 
increased number of lipid laden macrophages in the shoulder region. The matrix 
metalloproteinases (MMP), collagenase, gelatinase and stromolysin, secreted by the 
 7
 
activated macrophages can cause thinning of the fibrous cap by degrading the collagen 
content of the extracellular matrix. This can make the atherosclerotic plaques more 
vulnerable to rupture. Inflammatory cytokines also play a significant role in plaque 
instability and rupture. Cytokines such as TNFα and IL-1β have been shown to stimulate 
the production of 92 kDa gelatinase in macrophages without affecting tissue inhibitor of 
metalloproteinases-1 (TIMP-1), which is their natural inhibitor (Saren et al., 1996).  
 Increased IL-6 levels have been strongly correlated with atherosclerotic plaque 
instability and rupture in human subjects. In the left anterior descending coronary artery 
obtained from patients with ischemic cardiomyopathy, atherosclerotic plaques showed 
co-localization of IL-6 with macrophages in the shoulder region (Schieffer et al., 2000). 
The lipid-rich shoulder areas of plaques are the most vulnerable sites of plaque rupture 
(van der Wal et al., 1994, Schieffer et al., 2000). Similarly, Cheng et al. (2006) 
demonstrated increased expression of IL-6 in macrophage-rich areas of atherosclerotic 
plaques in ApoE-/- mice along with increased MMP activity. The authors suggested that 
IL-6 causes the increase in macrophage MMP activity that contributes to weakening of 
the fibrous cap and increased potential of plaque rupture. Increased plasma levels of IL-6 
have been detected in patients with acute myocardial infarction, coronary artery disease 
and peripheral artery disease (Erren et al., 1999, Ikeda et al., 1992). Rupture of plaques 
can generate circulating blood clots, when blood coming in contact with the tissue factor 
in the plaque coagulates (Libby, 2002). These clots can result in occlusion of blood 
vessels leading to ischemia, myocardial infarction or stroke. 
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1.2.4 Mouse models of Atherosclerosis 
Numerous animal species have been used to study the pathogenesis of 
atherosclerosis. These include pigeons, hamsters, rabbits, pigs and monkeys. However, 
several factors such as costs of maintenance and/or dissimilar disease progression status 
compared to humans have limited their use (Jaweiń et al., 2004). In recent years, the 
mouse has become a most useful model in the study of atherosclerosis. The low cost of 
maintenance, ease of breeding and genetic manipulation have made it the model of choice 
among biomedical researchers.  
The most commonly used mouse models in the study of atherosclerosis are low 
density lipoprotein receptor deficient mice (LDLr-/-), the ApoE-/- mice, and the 
apolipoprotein E and low density lipoprotein receptor (ApoE-/- /LDLr-/-) double 
knockout mice (Jaweiń et al., 2004, Daugherty, 2002). Mice are highly resistant to 
atherosclerosis and the lipid profile differs from that in humans. Mice carry most of the 
plasma cholesterol on high density lipoprotein (HDL), whereas humans carry 75% of 
cholesterol on low density lipoprotein (LDL) (Jaweiń et al., 2004). However, targeted 
gene deletion has enabled the generation of mouse models that develop atherosclerosis 
and have lipid profiles similar to humans. 
 ApoE is a 34 kD glycoprotein that is synthesized mainly by the liver. It is also 
produced by other tissues such as brain, spleen, lung, ovary, adrenal gland, kidney and 
muscles, and by cells types such as macrophages (Greenow et al., 2005). There are 3 
isoforms of ApoE; ApoE2, E3 and E4. The e3 allele is present in the majority of 
population. People with familial hypercholesterolemia have two copies of the e2 allele. 
ApoE is a major constituent of very low density lipoprotein (VLDL), but is also present 
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in HDL and chylomicron remnants. It promotes hepatic clearance of cholesterol by acting 
as a high affinity ligand for the hepatic LDL receptor. ApoE also binds another hepatic 
receptor, LDL receptor related protein (LRP), and has been implicated in the clearance of 
chylomicron remnants (Greenow et al., 2005). Other anti-atherogenic functions of ApoE 
include inhibition of LDL oxidation, inhibition of platelet aggregation, inhibition of SMC 
and endothelial cell proliferation and cholesterol efflux from macrophages. The hepatic 
LDL receptor, in addition to recognizing lipoproteins containing ApoE, is also 
responsible for the uptake of LDLs via interaction with ApoB-100. The ApoB-100 is an 
exclusive apolipoprotein associated with LDLs (Olofsson and Boren, 2005). Thus, the 
LDL receptor plays an important role in removal of excessive blood cholesterol. The 
increase in circulating LDLs is a risk factor for CVD. 
 The ApoE-/- mice develop atherosclerotic lesions/plaques that closely resemble 
the human condition. The development of plaques in the innominate artery of this mouse 
model has been well characterized and has been shown to closely resemble that of human 
condition with events such as intraplaque hemorrhage and loss of fibrous cap or plaque 
rupture (Rosenfeld et al., 2000). A major limitation of the ApoE-/- mouse model is that 
the lipid profiles are dissimilar from that of human subjects. In these mice, the plasma 
cholesterol is carried on VLDL (Ishibashi et al., 1994, Daugherty, 2002, Ohashi et al., 
2004), whereas in human subjects with atherosclerosis the majority of plasma cholesterol 
is carried on LDLs. On the other hand, the lipid profiles of LDLr-/- mouse model are 
more similar to that of human subjects with the majority of plasma cholesterol being 
carried on LDL and VLDL (Ishibashi et al., 1994, Jaweiń et al., 2004, Ohashi et al., 
2004). However, these mice develop lesions that consist of primarily lipid-laden 
 10
 
macrophages and lack advanced atherosclerotic lesions. Only when fed with high fat diet 
for longer periods do these mice develop advanced atherosclerotic lesions (Daugherty, 
2002, Ohashi et al., 2004). Compared to ApoE-/- or LDLr-/- mice alone, the ApoE-/- 
/LDLr-/- mice develop more marked atherosclerotic plaques (Jaweiń et al., 2004). The 
lipid profiles of this mouse model are more similar to that of humans as compared to 
either ApoE-/- or LDLr-/- mice, with the majority of plasma cholesterol being carried on 
LDLs when fed with normal mouse chow (Ishibashi et al., 1994). This makes the ApoE-/- 
/LDLr-/- mouse an ideal model to study the progression of atherosclerosis. 
 
1.3 Arsenic  
1.3.1 Environmental Significance of Arsenic  
Arsenic is a ubiquitous element in the environment present in rocks and soil, air 
and natural water. Exposure to arsenic via drinking water poses a significant threat to 
human health. Contamination of ground water occurs by mobilization of arsenic under 
natural conditions. Arsenic occurs as a major constituent in several minerals such as 
sulphides and oxides. Three mechanisms have been identified that result in arsenic 
mobilization under geochemical conditions (Smedley and Kinniburgh, 2002, Delemos et 
al., 2006). First, in arid or semi-arid environments, mineral weathering and high 
evaporation rates can result in development of high pH (>8.5) conditions that can cause 
desorption of adsorbed arsenic from mineral oxides or prevent it from being adsorbed. 
Second, strong reducing conditions result in the reductive dissolution of oxides such as 
iron and manganese, and release of arsenic by desorption. Third, competitive desorption 
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of arsenic by the presence of large concentrations of phosphate, bicarbonate and silicates 
can lead to increased ground water contamination with arsenic.  
In addition to the natural existence, arsenic is also widely distributed in the 
environment by human activities such as mining, smelting, pesticide application and 
manufacturing and use of products such as wood preservatives and dyes. In the United 
States, improper waste management from industrial and municipal sources, has created 
contaminated areas termed as ‘Superfund Sites’ that contain extremely high and 
dangerous levels of several environmental contaminants including arsenic. About 30% of 
the Superfund Sites in United States have excessive arsenic levels (Welch et al., 2000). 
Some of the sites have arsenic contamination introduced from human activities but many 
of the sites do not have a known source of contamination. A recent study performed at 
the Coakley Landfill Superfund Site in New Hampshire, a site contaminated with arsenic, 
chromium, lead, nickel, zinc and aromatic hydrocarbons, has reported that the 
concentrations of most of the contaminants diminished as a result of treatment by 
monitored natural attenuation that began in 1998, but the levels of dissolved arsenic 
increased over the same time interval (Delemos et al., 2006). This was due to the 
reductive release of arsenic from iron oxides. Natural biogeochemical processes are used 
to degrade contaminants. However, reducing environments created due to biodegradation 
of organic waste can cause the release of adsorbed arsenic from mineral oxides (Delemos 
et al., 2006). Although, this problem has only been identified in New Hampshire thus far, 
it could be a major problem all across the United States or in other countries where 
arsenic concentration in ground water is higher than the standard implemented by World 
Health Organization (WHO). 
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In the United States, the western regions have higher arsenic contamination of 
ground water (10 to >50 ppb) than the eastern regions (<10 ppb). However, there may be 
geographic ‘hotspots’ in the regions that have higher arsenic levels. In February 2002, the 
United States Environmental Protection Agency implemented the maximum contaminant 
limit (MCL) of 10 ppb for arsenic. The public water supply systems had to comply with 
this new standard by January 2006. Arsenic contamination of ground water is a 
worldwide problem. In 1993, the WHO also implemented the MCL of 10 ppb. In addition 
to the United States, Taiwan, Bangladesh, India (West Bengal), China, Vietnam, 
Hungary, Mexico, Romania and Argentina have high levels of arsenic in ground water 
ranging from 10-14,000 ppb (Wang and Wai, 2004, Smedley and Kinniburgh, 2002). 
 
1.3.2 Metabolism of Arsenic  
Exposure to arsenic can occur via food, water and air, of which drinking water 
(ground water) is a significant source of arsenic exposure in humans. Natural waters 
including drinking water mostly contain inorganic arsenic species; trivalent arsenite 
[As(III)] and pentavalent arsenate [As(V)] (Smedley and Kinniburgh, 2002). 
Concentrations of organic forms of arsenic are generally low or negligible in drinking 
water, but may occur in waters severely affected by industrial pollution (Smedley and 
Kinniburgh, 2002). The metabolism of arsenic in most mammals involves a series of 
reduction and oxidative methylation reactions during which As(V) is reduced to As(III) 
that is further metabolized to methylated species (Abernathy et al., 1999). The major site 
of arsenic methylation is the liver and the route of excretion is via the kidneys. There is 
considerable variation in arsenic methylation among mammalian species (Vahter, 2000).  
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 As(V) and As(III) are the major forms of inorganic arsenic present in drinking 
water. The mechanism of cellular uptake of arsenic varies with the valence state. As(V) is 
structurally similar to phosphate and its uptake into the cells is mediated through the 
phosphate carrier system (Huang and Lee, 1996). Two different mechanisms have been 
proposed for the cellular uptake of As(III); simple diffusion (Huang and Lee, 1996) and 
transport by mammalian aquaglyceroporins (Liu et al., 2002). As(V) has been shown to 
compete with phosphate and can deplete cellular energy levels by preventing the 
incorporation of phosphate into adenosine 5’-triphosphate (ATP). As(III) on the other 
hand is extremely thiol reactive and can affect the activities of several enzymes 
(Aposhian et al., 2004). The first step in the metabolism of arsenic involves the reduction 
of As(V) to As(III) by arsenate reductase in the presence of glutathione (GSH). The 
sulfhydryl-containing tripeptide, GSH, forms As(III)-(GS)3 complexes that may be 
substrates for methylating enzymes (Scott et al., 1993). Recent in vitro and in vivo studies 
using a rat model suggest that the key glycolytic enzyme, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), is the arsenate reductase enzyme in mammals (Neméti and 
Gregus, 2005, Gregus and Neméti, 2005, Neméti et al., 2006). However, further studies 
are needed to confirm this observation.  
 The next step in the metabolism of arsenic consists of a series of methylation 
reactions. As(III) is methylated to the pentavalent species, monomethyl arsonic acid 
[MMA(V)], by arsenite/MMA(III) methyltransferase in the presence of GSH. S-
adenosylmethionine (SAM) is the methyl donor in the methylation reactions (Buchet and 
Lauwerys, 1988). Using methyltransferases of rabbit liver, it has been shown that the 
arsenite methyltransferase and MMA(III) methyltransferase appear to have common 
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properties or may be part of the same protein or multienzyme complex (Zakharyan et al., 
1995). Furthermore, studies have reported that rat liver arsenite methyltransferase is a 
homologue of human cyt19 (Lin et al., 2002, Thomas et al., 2004). Recombinant rat and 
human cyt19 has been shown to methylate inorganic arsenite in in vitro conditions 
(Waters et al., 2004, Hayakawa et al., 2005). However, the expression and enzymatic 
activity of cyt19 in human liver has yet to be confirmed (Aposhian and Aposhian, 2006). 
The first methylation step is followed by alternating reduction of pentavalent arsenic to 
trivalent arsenic with the addition of a methyl group (Fig. 3). MMA(V) reductase in the 
presence of GSH catalyzes the reduction of MMA(V) to monomethylarsonous acid 
[MMA(III)] (Zakharyan and Aposhian, 1999) that is further oxidatively methylated to 
dimethylarsinic acid [DMA(V)] in the presence of arsenite/MMA (III) methyltransferase. 
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Fig. 3. Classical metabolic pathway of inorganic arsenic. 
Adapted from Hayakawa et al., 2005.  
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 In vitro studies have proposed the existence of As(III)-(GS)3  complexes (Scott et 
al., 1993). Kala et al. (2000) showed that arsenic-glutathione complexes are excreted in 
bile using the rat as in vivo animal model. This study detected the presence of arsenic 
triglutathione (ATG) and methylarsonic diglutathione (MADG) in bile samples. Based on 
these studies, a new metabolic pathway for inorganic arsenic has been proposed 
(Hayakawa et al., 2005) (Fig. 4). According to this pathway, As(V) is reduced to As(III) 
as described previously in the original pathway. As(III) complexes with GSH in the 
presence of SAM and cyt19 to form ATG that in turn acquires 2 methyl groups forming 
MADG and dimethylarsinic glutathione (DMAG), respectively. MADG is then 
hydrolyzed to MMA(III), which is further oxidized to MMA(V). Similarly, DMAG is 
converted to DMA(V). This new pathway is in its infancy and additional studies will be 
needed to confirm the reaction steps. Also, the formation of various intermediates in this 
pathway has been demonstrated in in vitro conditions and needs further in vivo 
confirmation (Thomas et al., 2007, Aposhian and Aposhian, 2006).  
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Fig. 4. New metabolic pathway of inorganic arsenic  
Adapted from Hayakawa et al., 2005. 
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 The bulk of data on metabolism of arsenic has been obtained from in vitro cell-
free studies using rat liver cytosol, purified arsenic methyltransferase enzyme or rat 
hepatocytes. Styblo et al. (1999) documented the metabolism of arsenic using primary 
human hepatocytes. According to this study, human hepatocytes exposed to As(III) 
showed a steady decline in As(III) in the culture medium with simultaneous increase in 
MMA and DMA species. The formation of DMA accounted for 60% of the arsenic in the 
culture medium. In contrast, exposure of human hepatocytes to As(V) resulted in the total 
methylation yield (MMAs and DMAs) of less than 3%, probably due to the lower uptake 
of As(V) by hepatocytes (Styblo et al., 1999). However, it has been shown that majority 
of the ingested As(V) is rapidly reduced to As(III), probably in the blood (Vahter, 2002). 
Therefore, As(III) could be the major inorganic arsenic species metabolized by liver 
hepatocytes. 
In mammals, liver is the primary organ for arsenic methylation. Other organs such 
as kidneys, lungs and testes also have arsenic methylating activity (Vahter, 2002). The 
major route of arsenic excretion is via the kidneys. MMA(V) and DMA(V) are the main 
metabolites found in the urine of humans exposed to arsenic. Variation in arsenic 
methylation between different populations groups have been reported based on the 
metabolites analyzed in urine samples (Vahter, 2002). Several factors such as age, 
gender, nutrition and polymorphisms in genes regulating the methyltransferases have 
been suggested to play a role in the inter-individual variation in arsenic metabolism. 
Irrespective of the arsenic concentration and the extent of exposure, on average, the 
human urine contains 10-30% inorganic arsenic, 10-20% MMA(V) and 60-80% 
DMA(V) (Vahter, 2000, Vahter, 2002). Considerable variation in the methylation of 
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arsenic has been reported among other mammalian species (Vahter, 1994). Compared to 
human subjects, animal species such as rat, mouse, dog, rabbit and hamster excrete very 
little MMA(V). The excretion of DMA(V) and inorganic arsenic also differs between 
species. Interestingly, the marmoset monkey and the chimpanzee lack the ability to 
methylate arsenic (Vahter, 1994, Vahter, 2000). This points out the species specific 
differences in the arsenic methylating enzymes and therefore, the results of arsenic 
metabolism studied using different species should be interpreted with caution. 
 
1.3.3 Arsenic and Reactive Species  
As(III) (<5 μM) has been shown to produce reactive oxygen species (ROS) 
including superoxide anion and hydrogen peroxide, but not reactive nitrogen species 
(RNS) such as nitric oxide in porcine aortic endothelial cells (Barchowsky et al., 1999). 
Increased levels of plasma superoxide have been positively correlated with arsenic 
concentration in whole blood of human subjects exposed to high arsenic levels in 
northeastern Taiwan (Wu et al., 2001). As(III) (>5 μM) has been shown to increase levels 
of nitric oxide in bovine aortic endothelial cells (Lynn et al., 1998; Liu and Jan, 2000). 
Furthermore, As(III) (>0.25 μM) has been shown to generate the RNS, peroxynitrite, in 
bovine aortic endothelial cells (Bunderson et al., 2002). Peroxynitrite is formed by the 
rapid reaction of superoxide with nitric oxide and is a strong oxidizing and nitrating 
molecule. Peroxynitrite can induce protein modifications via oxidation/nitration of 
cysteine, tyrosine, methionine and tryptophan residues (Pryor and Squadrito, 1995, Radi 
et al., 2001, Beckman, 1996). Formation of peroxynitrite can cause lipid peroxidation 
(Radi et al., 1991), generate oxLDLs (Keaney, 2000) and activate nuclear factor-kappa B 
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(NF-κB) (Cooke and Davidge, 2002, Matata and Galinanes, 2002). Peroxynitrite has been 
reported to interfere with cellular processes and signal transduction pathways by 
oxidation as well as nitration of proteins (Klotz et al., 2002). The detection of 
nitrotyrosine in biological samples has been used as a marker for the presence of 
peroxynitrite (Ischiropoulos, 1998, Beckman and Koppenol, 1996). The presence of 
nitrotyrosine has been observed in human atherosclerotic plaques (Beckman et al., 1994, 
Cromheeke et al., 1999). Also, nitrotyrosine formation has been detected in the 
atherosclerotic plaques of ApoE-/- /LDLr-/- mice exposed to As(III) in drinking water 
(Bunderson et al., 2004). 
 Contradictory to the increase in nitric oxide production in endothelial cells, it was 
observed that Chinese individuals exposed to arsenic in drinking water had reduced 
serum levels of nitric oxide metabolites indicating impaired nitric oxide generation (Pi et 
al., 2000). This observation was confirmed in rabbits exposed to 5 ppm As(V) in drinking 
water for 18 weeks (Pi et al., 2003). As(V) or As(III) (100 μM) were shown to suppress 
the activity of endothelial nitric oxide synthase (eNOS), the enzyme responsible for 
catalyzing production of nitric oxide, in the homogenates of human umbilical vein 
endothelial cells (HUVEC) (Pi et al., 2000). It was also observed that treatment of 
HAECs with As(III) (>10 μM) reduced eNOS activity, thereby suppressing nitric oxide 
production (Lee et al., 2003). However, Kao et al. (2003) demonstrated that As(III) (<5 
μM) induces an increase in eNOS protein synthesis and production of nitric oxide in 
HUVECs. Therefore, it appears that the production of reactive species with arsenic 
treatment differs with the experimental conditions such as cell line in consideration and 
concentration of arsenic. 
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1.3.4 Arsenic and Cardiovascular Disease 
Epidemiological studies have associated arsenic exposure with the development 
of CVDs. In the United States, a study conducted in 30 counties investigated the 
ecological relationship between population-weighted mean arsenic concentration in 
public water supplies and mortality from vascular disease from 1968 to 1984 (Engel and 
Smith, 1994). According to this study, exposure to arsenic levels greater than 20 ppb 
were associated with increased mortality from various CVDs such as coronary heart 
disease, peripheral arterial diseases and stroke (Engel and Smith, 1994, Navas-Acien et 
al., 2005). In Bangladesh, where the arsenic concentration is ground water ranges from 
10-14,000 ppb (Wang and Wai, 2004), a study was conducted to determine the 
relationship between arsenic exposure and development of hypertension. After adjusting 
for age, sex and body mass index, a significant dose-response relationship was observed 
between concentration of arsenic in drinking water and prevalence of hypertension 
(Rahman et al., 1999). Arsenic exposure through drinking water has also been associated 
with the development of ischemic heart disease and carotid atherosclerosis based on 
studies conducted in Taiwan, where arsenic levels range from 100-1810 ppb (Wang and 
Wai, 2004). Wang et al. (2002) documented the effect of long-term arsenic exposure and 
extent of carotid atherosclerosis. By adjusting for the risk factors of atherosclerosis 
including age, sex, hypertension, diabetes mellitus, cigarette smoking, alcohol 
consumption, waist-to-hip ratio and cholesterol, a significant association was observed 
between arsenic exposure and prevalence of carotid atherosclerosis. A dose-response 
relationship was observed between the prevalence of carotid atherosclerosis and each of 
the three indices of arsenic exposure; duration of consumption of arsenic contaminated 
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water, average arsenic concentration in water and cumulative arsenic exposure (Wang et 
al., 2002). Atherosclerosis is the underlying cause of CVDs including ischemic heart 
disease. Tseng et al. (2003) documented the association of long-term arsenic exposure 
with ischemic heart disease. After adjusting for risk factors, prevalence rates for ischemic 
heart disease positively correlated with cumulative arsenic exposure (arsenic 
concentration in drinking water and duration of exposure) of 0.1 to > 15 mg/l-year. Thus, 
epidemiological studies strongly associate arsenic exposure with development of CVD. 
 Several confounding factors can obscure or underestimate the severity of arsenic 
effects. For example, a majority of epidemiological studies have taken into account 
arsenic exposure through drinking water, but have not accounted for exposure due to 
other sources such as contaminated food or cooking water (Navas-Acien et al., 2005). 
Controlled animal studies have helped eliminate the confounding factors and confirm the 
association between high levels of arsenic exposure and development of CVD. It has 
been observed that exposure to 20 and 100 ppm As(III) in drinking water for 24 weeks 
accelerates atherogenesis in ApoE-/- mice (Simeonova et al., 2003). Our laboratory has 
previously demonstrated that chronic exposure (18 weeks) to 10 ppm As(III) in drinking 
water exacerbates atherosclerotic plaque formation in ApoE-/- /LDLr-/- mice (Bunderson 
et al., 2004). In addition, As(III) exposure has been documented to cause blood vessel 
dysfunction in a rat model. It was observed that intravenous injection of 1 mg/kg As(III) 
solution suppressed the acetylcholine-induced reduction of blood pressure (Lee et al., 
2003) and augmented the phenylephrine-induced increase in blood pressure (Lee et al., 
2005) in conscious male Sprague-Dawley rats. Thus, As(III) exposure possibly impairs 
vascular homeostasis and thereby contributes to the development of CVDs.  
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 The vascular endothelium plays a critical role in the atherosclerotic disease 
process. In vitro and in vivo studies suggest that arsenic can modulate the inflammatory 
mediators involved in the process of atherosclerosis, generate oxidative and nitrosative 
stress and cause transcription factor activation and gene expression relevant to 
endothelial dysfunction. It has been observed that treatment of HAECs with 5 or 50 μM 
As(III) induces IL-8 gene expression with simultaneous increase in AP-1 and NF-κB 
DNA binding activity (Simeonova et al., 2003). Expression of the inflammatory 
mediator, IL-8, is regulated by the transcription factors AP-1 and NF-κB. Oxidant-
sensitive activation of NF-κB has been documented in porcine aortic endothelial cells 
exposed to 2-5 μM As(III) (Barchowsky et al., 1996). In addition, As(III) (>5 μM) has 
been shown to increase the expression of inflammatory mediators such as 
cyclooxygenase-2 (Bunderson et al., 2002) and leukotriene E4 (Bunderson et al., 2004) in 
bovine aortic endothelial cells as well as ApoE-/- /LDLr-/- mice exposed to 10 ppm 
As(III) for 18 weeks. As(V) and As(III) have also been related to the impairment of nitric 
oxide production in the vasculature as described previously in section 1.3.3 (Lee et al., 
2003, Pi et al., 2003). Nitric oxide plays an important role in vascular homeostasis. This 
may contribute to arsenic-related hypertension as well as atherosclerosis. As(III) (>10 
μM) has also been shown to cause platelet aggregation and thrombus formation (Lee et 
al., 2002). Thrombus formation could result in fatal consequences such as ischemic heart 
disease, myocardial infarction as well as stroke. 
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1.4 The Endothelium 
1.4.1 Endothelial Junctions 
Endothelial cells form two major types of cell-cell adhesion complexes, adherens 
junctions and tight junctions. In addition, endothelial cells have gap junctions that 
mediate cell-cell communication. The adherens junctions and tight junctions exist 
intermingled with each other at the boundaries of endothelial cells (Bazzoni and Dejana, 
2004). The adherens junctions are thought to organize before the tight junctions and 
regulate the assembly of tight junctions (Liebner et al., 2006). The junctional complexes 
are in part responsible for maintaining vascular homeostasis. Endothelial cells are a 
heterogeneous population and there are differences in the cell-cell junctions between 
endothelial cells from different vascular beds. For example, the tight junctions in brain 
endothelial cells are well developed and maintain strict control of permeability. The 
venous endothelial cells on the other hand have poorly organized tight junctions to allow 
dynamic movement of plasma proteins. The arterial endothelial cells have well developed 
tight junctions and adherens junctions to maintain a semipermeable barrier. Accordingly, 
it has been observed that HAEC and HUVEC show different permeability levels when 
exposed to histamine (Ikeda et al., 1999). The authors showed that treatment of HAECs 
with various concentrations of histamine showed no difference in permeability as 
compared to untreated cells, whereas HUVECs showed a significant concentration-
dependent increase in permeability. Under normal physiological conditions arterial 
endothelial cells allow the passage of molecules smaller than 4 nm through the 
intercellular junctions (Tedgui, 1996).  
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1.4.2 Adherens Junction of Endothelial Cells  
The molecular components of adherens junction includes the endothelial cell 
specific vascular endothelial (VE)-cadherin and the catenins. VE-cadherin belongs to the 
cadherin family of transmembrane glycoproteins. It consists of a cytoplasmic domain and 
an extracellular region with five domains (EC1-EC5) (Fig. 5). VE-cadherin promotes 
homotypic adhesion between cells via its extracellular domains in a calcium (Ca2+) 
dependent manner. The EC1 domain of the extracellular region is proposed to participate 
in the formation of cis/trans dimers and promote stable homophilic cell-cell adhesion 
(Ivanov et al., 2001, Bazzoni and Dejana, 2004, Steinberg and McNutt, 1999). The 
homophilic adhesion characteristics of cadherins were discovered when it was observed 
that co-culture of cells expressing different types of cadherins results in aggregation of 
cells with identical cadherins (Nose et al., 1988, Ivanov et al., 2001). The intercellular 
adhesion mediated by VE-cadherin is Ca2+ sensitive. It has been observed that exposure 
of HUVECs to 3 mM Ca2+ chelator, EGTA, causes the loss of VE-cadherin 
immunostaining. Also, exposure of HUVECs to low Ca2+ (<10-7 M) in serum free 
medium was observed to induce intercellular gaps that were reversible with the 
introduction of medium containing serum and Ca2+ (Schnittler et al., 1997). VE-cadherin 
along with other cadherins such as epithelial (E), neural (N), placental (P) and retinal (R) 
belongs to the class of type I classical cadherins. The type II classical cadherins include 
the recently discovered cadherins that are yet to be characterized (Ivanov et al., 2001). 
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Fig. 5. The cadherin-catenin complex and actin cytoskeleton.  
Reprinted, with permission, from the Annual Review of Cell and Developmental 
Biology, Volume 13 ©1997 by Annual Reviews www.annualreviews.org  
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 The cytoplasmic domain of VE-cadherin associates with β-catenin that in 
turn is linked to the actin cytoskeleton via α-catenin (Ivanov et al., 2001) (Fig. 3). This 
association is extremely important to maintain endothelial monolayer integrity. It has 
been observed that mutant VE-cadherin with a truncated cytoplasmic domain, promotes 
cell-cell adhesion via the extracellular domains but the association with β-catenin and 
actin cytoskeleton is severely impaired (Navarro et al., 1995). As a result, the junctional 
stability is compromised with increased endothelial permeability. The formation of a 
stable cadherin-catenin complex has also been shown to be important for endothelial cell 
survival as it activates phosphoinositide 3-kinase (PI3K) and Akt phosphorylation 
(Carmeliet et al., 1999, Liebner et al., 2006). Other catenins such as γ-catenin (also 
known as plakoglobin) and p120 catenin have been shown to associate with the adherens 
junction complex. γ-Catenin has been shown to associate with the VE-cadherin in 
HUVECs after formation of stable cell-cell adhesions and is proposed to strengthen the 
adherens junction complex (Lampugnani et al., 1995, Schnittler et al., 1997). p120 
catenin associates with the membrane proximal region of the cytoplasmic domain of VE-
cadherin and does not interact with any of the other catenins. Its role in cell-cell adhesion 
has yet to be elucidated (Bazzoni and Dejana, 2004, Anastasiadis and Reynolds, 2000). 
 The tyrosine phosphorylation of adherens junction proteins plays a critical role in 
the formation and maintenance of stable cell-cell adhesions. Tyrosine phosphorylation of 
VE-cadherin and β-catenin is a normal physiological process. It has been observed using 
HUVECs that loosely or recently confluent cells have increased tyrosine phosphorylation 
of VE-cadherin and β-catenin (Lampugnani et al., 1997). The tyrosine phosphorylation 
levels decrease when endothelial cells reach the fully confluent state. Furthermore, if the 
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confluent endothelial monolayer is damaged, the cells at the migrating front show 
increased tyrosine phosphorylation of VE-cadherin and β-catenin (Lampugnani et al., 
1997). The tyrosine phosphorylation of VE-cadherin and/or β-catenin can alter their 
interaction with each other as well as the actin cytoskeleton. Association of adherens 
junction proteins with the actin cytoskeleton is extremely important for maintaining the 
mechanical strength and stability of the endothelial monolayer. The endogenous 
mediator, histamine (10-4 M), has been shown to increase tyrosine phosphorylation of 
both β-catenin and VE-cadherin in HUVECs or human dermal microvascular endothelial 
cells (HMEC). This was accompanied by a decrease in the association of VE-cadherin 
with the actin cytoskeleton as analyzed by the reduced distribution of VE-cadherin in the 
detergent insoluble fraction (Andriopoulou et al., 1999). Intercellular gaps with increased 
permeability were also observed with histamine treatment, implying that the VE-cadherin 
mediated adhesion was compromised (Andriopoulou et al., 1999). Vascular endothelial 
growth factor (VEGF) (50-100 ng/ml) has been shown to increase tyrosine 
phosphorylation of VE-cadherin and β-catenin causing the loosening of adherens 
junctions and increased permeability in HUVECs (Esser et al., 1998). The increase in 
permeability due to disruption of the endothelial monolayer could accelerate 
atherogenesis by increasing the transmigration of oxLDLs and monocytes into the intima 
of blood vessels. Accordingly, it has been observed that injection of anti-VE-cadherin 
blocking antibody into the tail vein of mice increased vascular permeability with damage 
to the endothelial lining and deposition of monocytes and neutrophils in the areas of 
exposed basement membrane (Corada et al., 1999). Similarly, another study documented 
that intravenous injection of anti-VE-cadherin antibody increases vascular permeability 
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and accelerates neutrophil entry into chemically inflamed mouse peritoneum (Gotsch et 
al., 1997). 
 There are several protein tyrosine kinases such as Fyn, Fer, cMet, Abl and Src as 
well as protein tyrosine phosphatases such as PTP1B, SHP1, SHP2 and VE-PTP that 
have been shown to associate with and modulate the phosphorylation state of the 
cadherin-catenin complex (Lilien and Balsamo, 2005, Yuan, 2003, Bogatcheva et al., 
2003, Xu et al., 2004, Daniel and Reynolds, 1997). The exact role of each of the tyrosine 
kinases and phosphatases has yet to be elucidated, but each of these might act in an 
unique temporal and spatial context to maintain stable cadherin-catenin mediated cell-cell 
adhesion. It has been observed that the endothelial cell-specific protein tyrosine 
phosphatase, VE-PTP, reduces the tyrosine phosphorylation of VE-cadherin induced by 
VEGF and strengthens the cell-cell adhesion (Nawroth et al., 2002, Bazzoni and Dejana, 
2004). Phosphorylation of β-catenin at tyrosine 654 by Src has been shown to cause a 
fivefold reduction in its affinity for E-cadherin (Roura et al., 1999), which belongs to the 
same class of type I classical cadherins as VE-cadherin (Ivanov et al., 2001). Therefore, 
the phosphorylation/dephosphorylation states of the cadherin-catenin complex may be 
modulated by complex interplay between tyrosine kinase and phosphatase activities.  
 
1.5 Stress Fibers 
Endothelial cells contain two pools of actin. Globular actin (G-actin) is the 
monomeric form, which can undergo polymerization to form filamentous actin (F-actin) 
(DuBose and Haugland, 1993, Oosawa, 2001). In nonmuscle cells such as endothelial 
cells and fibroblasts, F-actin is involved in cell activities such as locomotion, cell 
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adhesion, cytokinesis and maintenance of cell shape. Under normal physiological 
conditions and in confluent endothelial cell culture, F-actin forms the dense peripheral 
band (DPB) that is a thin layer of actin microfilaments near the plasma membrane (Wong 
and Gotlieb, 1990, Guyton et al., 1989, Colangelo et al., 1998). F-actin also forms the 
cytoplasmic stress fibers that extend from the cells periphery towards the central regions 
or in some cases crossing the entire cell. Very few stress fibers may be visible in normal 
endothelial cells, but can be dramatically increased in pathological conditions such as 
hypertension and atherosclerosis (White et al., 1983, Guyton et al., 1989, Colangelo et 
al., 1998). F-actin of the DPB is linked to the cadherin-catenin complex and plays a 
critical role in maintaining endothelial monolayer integrity. Actin reorganization 
associated with disruption of the endothelial barrier is characterized by increased stress 
fiber density and reduction or loss of the DPB (Lum and Roebuck, 2001). 
 Stress fibers consist of several proteins such as myosin, tropomyosin and α-
actinin intermittently associated with the F-actin filaments (Byers et al., 1984). Stress 
fibers are contractile elements. Stress fibers isolated from cultured human foreskin 
fibroblast and bovine aortic endothelial cells have been shown to contract/shorten to 
approximately 23% of the initial length (Katoh et al., 1998). Mitogenic stimulation of 
3T3 fibroblast with 10% serum or 10 nM thrombin has been shown to induce contraction 
of stress fibers accompanied by retraction of cell edges (Giuliano and Taylor, 1990).  
The formation of stress fibers is regulated by the phosphorylation of myosin light 
chain (MLC) of myosin II. Phosphorylation of MLC causes a conformational change in 
the myosin molecule and promotes its association with actin, resulting in the assembly of 
stress fibers (van Nieuw Amerongen and van Hinsbergh, 2001). The Ca2+/calmodulin-
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dependent myosin light chain kinase (MLCK) is considered to be the primary regulator of 
MLC phosphorylation, since the Km of MLCK for MLC is 52 μM/L. The small GTPase, 
Rho, has also been shown to modulate phosphorylation of MLC and development of 
stress fibers by several mechanisms (van Nieuw Amerongen and van Hinsbergh, 2001). 
Rho GTPase has been shown to phosphorylate MLC through Rho kinase. The Km of Rho 
kinase for MLC is 0.91 μM/L. Rho GTPase has also been shown to inhibit the myosin 
phosphatase type 1 (PP1M) responsible for dephosphorylation of MLC. In addition, Rho 
GTPase has been proposed to induce stress fiber formation by induction of actin 
polymerization and inhibition of actin depolymerization (van Nieuw Amerongen and van 
Hinsbergh, 2001).  
Disruption of endothelial monolayer integrity and increased endothelial 
permeability have been associated with the development of stress fibers. It has been 
shown that exposure of endothelial cells to apolipoprotein(a) component of 
lipoprotein(a), a risk factor for atherosclerotic disorders, induces cytoplasmic stress fibers 
with simultaneous loss of the DPB and VE-cadherin dispersion. This was accompanied 
by cell retraction, intercellular gap formation and increased endothelial permeability in 
HUVEC as well as HCAECs (Pellegrino et al., 2004). The formation of stress fibers was 
shown to be dependent on increased phosphorylation of MLC by Rho GTPase and Rho-
kinase. Inhibition of Rho GTPase and Rho-kinase by pretreating HUVECs with C3 
transferase and Y-27632, respectively, inhibited MLC phosphorylation, abolished the 
formation of stress fibers and restored VE-cadherin at the cell-cell junctions. The 
phosphorylation of MLC was also found to be Ca2+ dependent, although no increase in 
intracellular Ca2+ was observed (Pellegrino et al., 2004). Other mediators of vascular 
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permeability such as thrombin and histamine have also been shown to induce formation 
of stress fibers. It has been observed that treatment of HUVECs with 1 μM α-thrombin or 
histamine increases intracellular Ca2+ levels and formation of stress fibers with a 
simultaneous increase in endothelial permeability (Ehringer et al., 1996, Ehringer et al., 
1999). Sandoval et al. (2001) further demonstrated that exposure of HUVECs to 10 nM 
thrombin increases intracellular Ca2+ levels and MLC phosphorylation with a 
concomitant increase in stress fibers. An increase in endothelial permeability was also 
recorded. The authors suggest the involvement of Rho GTPase mediated signaling in the 
observed effects. 
The in vivo presence of stress fibers has been reported during hypertension and 
atherosclerosis. It was observed that the aortic endothelium of spontaneously 
hypertensive rats had more than a twofold higher proportion of endothelial cells 
containing stress fibers than the age and sex-matched Wistar-Kyoto normotensive rats 
(White et al., 1983). The stress fibers in the Wistar-Kyoto normotensive rats were also 
thinner as compared to those in spontaneously hypertensive rats. The development of 
stress fibers in atherosclerotic conditions was demonstrated using New Zealand white 
rabbits. Guyton et al. (1989) demonstrated that 80% of the endothelial cells from control 
aortas had either no stress fibers or were narrow, thin and no more than 1/3 the length of 
the cell, if present. The same pattern of expression was also found in nonlesioned areas of 
experimental cholesterol fed animals. The stress fibers in endothelial cells near and over 
the atherosclerotic lesions were much more numerous than those observed in control 
animals and extended the entire length of the endothelial cells. Furthermore, Colangelo et 
al. (1998) characterized the stress fibers in early, minimal, intermediate and advanced 
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lesions in rabbits fed with a high fat diet. The early lesions were characterized by 
adhesion of leukocytes to the endothelium, minimal lesions consisted of few cells in the 
subendothelium, intermediate lesions had numerous subendothelial leukocytes and the 
advanced lesions consisted of several layers of leukocytes. The endothelial areas with 
early lesions showed normal actin distribution as DPB. The minimal lesion areas showed 
few cytoplasmic stress fibers whereas the intermediate lesion areas showed a decrease of 
DPB and prominent cytoplasmic stress fibers. Isolated thick bundles of stress fibers were 
also observed. Interestingly, the areas of advanced lesions showed no or few cytoplasmic 
stress fibers (Colangelo et al., 1998). The authors suggested that the pattern of expression 
of stress fibers signifies their involvement in the early stages of atherogenesis by 
increasing endothelial permeability and transmigration of monocytes. 
 
1.6 Protein Kinase C  
1.6.1 Structure of Protein Kinase C 
The protein kinase C (PKC) family members are serine/threonine kinases and 
have been grouped into 3 classes based on their structural and enzymatic properties: 
classical or conventional, novel and atypical PKC isotypes (Mellor and Parker, 1998, 
Newton, 2001). The classical PKC (cPKC) includes α, the alternatively spliced β1 and β2, 
and γ subtypes. The β1 and β2 isoforms differ at the C-terminal kinase domain; PKCβ1 has 
50 residues and PKCβ2 has 52 residues (Kawakami et al., 2002). The novel PKC (nPKC) 
consist of η, ε, δ and θ subtypes, and the ι and ζ subtypes belong to the atypical class of 
PKC (aPKC). All members contain a regulatory region and a kinase domain that are 
connected with each other by a proteolytically labile hinge region. The regulatory region 
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consists of the pseudosubstrate site, and C1 and C2 domains. The kinase domain consists 
of binding sites for ATP and substrate. The pseudosubstrate site of the regulatory region 
interacts with the kinase domain and is responsible for suppression of PKC catalytic 
activity. The C1 and C2 domains are the membrane-targeting modules. The C1 domain 
binds diacylglycerol (DAG) and phosphatidyl serine (PS), and the C2 domain binds Ca2+. 
The regulatory region of the cPKCs includes the C1 and C2 domains and requires Ca2+, 
DAG and PS for activation. The nPKCs also consist of C1 and C2 domains in the 
regulatory region but the C2 domain does not bind Ca2+ and therefore requires only DAG 
and PS for activation. The aPKCs possess only the C1 domain and require only PS for 
activation (Mellor and Parker, 1998, Newton, 2001).  
 
1.6.2 Regulation of Classical Protein Kinase C isoforms 
 The activation and physiological function of cPKC isoforms is strictly regulated 
by phosphorylation, binding of cofactors and subcellular localization (Newton, 2001). 
Phosphorylation is the first step that primes newly synthesized cPKCs for catalytic 
activity. cPKC isoforms are phosphorylated at one serine and two threonine residues in 
the kinase domain. Phosphoinositide dependent kinase-1 (PDK-1) phosphorylates a 
threonine residue (T497 in case of PKCα, T500 for PKC β1 and β2 and T514 for PKCγ), 
following which the other threonine and serine residues are autophosphorylated. The 
phosphorylation by PDK-1 is proposed to be constitutive, but dependent on a specific 
conformation of cPKC (Newton, 2001, Sonnenburg et al., 2001, Newton, 2003). The 
phosphorylated PKC molecule remains inactive in the cytosol until activated by cofactors 
(Ca2+, DAG and PS). An increase in intracellular Ca2+ promotes its binding to 
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phosphorylated PKC in the cytosol. Ca2+ binding triggers translocation of phosphorylated 
PKC to the membrane and binding of DAG and PS for complete activation. Phorbol 
esters that mimic DAG, are extremely potent activators of cPKCs and can cause 
membrane translocation and activation without the need for PS or increased intracellular 
Ca2+ (Newton, 2001). Apart from the cofactor based activation of cPKCs, their activity 
has also been shown to be modulated by tyrosine phosphorylation (Konishi et al., 1997), 
oxidative modification of the regulatory region (Gopalakrishna and Anderson, 1989), and 
proteolysis at the hinge region (Kishimoto, et al., 1989).  
The subcellular localization of the PKC isoforms plays a critical role in their 
biological activity. Several proteins have been identified that interact with the different 
PKC isoforms and position them in specific intracellular compartments or in close 
proximity to the substrates, phosphatases or other kinases (Ron and Kazanietz, 1999). For 
example, it has been observed that syndecan-4, a member of the transmembrane matrix 
binding proteoglycans, associates with PMA activated PKCα and potentiates its activity. 
This complex may colocalize to the focal adhesions (Oh et al., 1997). Another anchoring 
protein, receptor for activated C kinase 1 (RACK1), has been shown to associate only 
with activated PKCβ2 and regulate its intracellular localization (Newton, 2001, Ron and 
Kazanietz, 1999). Interestingly, it was observed that the association of activated PKC 
with RACK1 promotes the binding of RACK1 with Src tyrosine kinase (Chang et al., 
2001). Thus, RACK1 possibly mediates the cross talk between serine/threonine and 
tyrosine kinase signaling pathways (Bauman and Scott, 2002, Chang et al., 2001). Further 
identification and characterization of PKC binding proteins will aid in our understanding 
of the complex regulation of PKC activities. Also, depending on cell types and 
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experimental conditions, the activation and translocation of PKCs may differ. It was 
observed that in response to different stimulating agents, PKCα translocation varies 
within the same cell type and experimental conditions. Treatment of A7r5 smooth muscle 
cells with 10-8 M phorbol 12, 13 dibutyrate, 10-5 M thapsigargin, 2 x 10-5 M A23187 or 
10-6 M angiotensin II induced a varied spatial and temporal response in PKCα 
translocation (Li et al., 2002). Furthermore, varying subcellular localization of the 
different PKC isoforms (α, β1, β2, γ, δ, ε, ζ and η) was observed when NIH 3T3 
fibroblasts were stimulated with 100 nM 12-O-tetradecanoylphorbol-13-acetate (TPA) 
(Goodnight et al., 1995).  
  
1.6.3 Classical Protein Kinase C and Regulation of the Endothelial barrier 
Tyrosine phosphorylation of adherens junction proteins as well as development of 
stress fibers could adversely affect the endothelial barrier. The cPKC isoforms, α and β, 
have been implicated in the modulation of the endothelial barrier. It has been observed 
that activation of PKCα by 50 nM α-thrombin activates Rho GTPase by dissociating it 
from guanine dissociation inhibitor (GDI) in HUVECs (Mehta et al., 2001). The GDI 
sequesters Rho in its GDP bound form and thereby prevents its activation (Rolfe et al., 
2005). Activated PKCα was also found to associate with Rho GTPase (Mehta et al., 
2001). Activation of Rho GTPase has been shown to induce stress fiber formation. Also, 
activation of PKCα in HUVECs by 10 nM thrombin has been shown to cause MLC 
phosphorylation with concomitant increase in stress fibers and endothelial permeability 
(Sandoval et al., 2001). VEGF (100 ng/ml) has been shown to induce tyrosine 
phosphorylation of β-catenin in a PKC dependent manner in bovine pulmonary artery 
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endothelial cells, although the exact PKC isoform involved was not determined (Cohen et 
al., 1999). Wang et al. (2004) further showed that 100 ng/ml VEGF mediates activation 
of PKCβ1 and β2 isoforms in HUVECs and disrupts the association of VE-cadherin with 
β-catenin. Inhibition of PKCα has been demonstrated to inhibit the ischemia-induced 
endothelial permeability in porcine endothelial cells (Hempel et al., 1999). In vivo use of 
PKCβ inhibitors in the treatment of vascular complications in diabetes mellitus has been 
reported (Meier and King, 2000). Therefore, PKCs play a significant role in regulation of 
the endothelial barrier.  
 
1.7 Summary  
Arsenic exposure has been associated with the development of CVD including 
atherosclerosis. During the atherosclerotic process, the semipermeable property of the 
endothelium is severely impaired. The endothelium is the most important barrier between 
the blood and vessel wall, and adherens junction proteins play a significant role in the 
maintenance of this barrier. The cadherin-catenin complex of the adherens junction 
associates with the actin cytoskeleton that provides the strength and stability to the 
endothelial barrier. The effects of arsenic on the proteins involved in maintaining 
endothelial integrity remain unknown. Endogeneous mediators have implicated cPKCs in 
the modulation of endothelial integrity. However, the effects of arsenic on PKC 
activation vary with the experimental conditions. Arsenic has been shown to induce 
peroxynitrite generation that can modulate signaling pathways. Controversial data exist 
regarding the effects of peroxynitrite in activation of PKCs. Using human aortic 
endothelial cells (HAECs), our laboratory tested the hypothesis that arsenic, via 
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generation of peroxynitrite, induces the activation of cPKC (α and β) isotypes resulting in 
the loss of endothelial monolayer integrity characterized by formation of actin stress 
fibers, disruption of adherens junctions and increased endothelial permeability. 
Epidemiological and animal studies have established the relationship between arsenic 
exposure and atherosclerosis. But the time- and concentration-dependent effects of 
arsenic in the development of atherosclerosis remain unknown. Therefore, we analyzed 
the effects of low and environmentally relevant concentrations of arsenic on 
atherogenesis using the ApoE-/- /LDLr-/- mouse model.  
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Chapter 2 
Time- and Concentration-Dependent Effects of Arsenic on 
Atherogenesis in ApoE-/- /LDLr-/- Mice 
 
2.1 Abstract 
Exposure to arsenic through drinking water has been associated with 
cardiovascular disease. In the present study, the effects of environmentally relevant 
concentrations of arsenic in the development of atherosclerosis were investigated using 
the well-established animal model of human atherosclerosis, mice deficient in 
apolipoprotein E and low density lipoprotein receptor (ApoE-/- /LDLr-/-). The temporal 
effects of arsenic were determined by exposing the mice to 10 ppm sodium arsenite 
[As(III)] in drinking water for 5 or 10 weeks. Histology revealed that mice treated with 
As(III) showed an increasing trend in atherosclerotic plaque formation within the 
innominate arteries compared to the controls at both 5 and 10 weeks. Analysis of 
interleukin-6 (IL-6) levels in the serum obtained from mice treated with As(III) for 10 
weeks showed an increasing trend compared to the control mice. These results suggest 
that As(III) contributes to atherogenesis at an early stage of the disease. The 
concentration-dependent effects of arsenic were analyzed by exposing the ApoE-/- 
/LDLr-/- mice to 1, 5 and 10 ppm As(III) in drinking water for 20 weeks. A significant 
increase in occlusion of the innominate arteries was observed with 1 and 5 ppm As(III). 
An increasing trend in occlusion was observed with 10 ppm As(III), and serum IL-6 
levels were significantly elevated in this group. These results demonstrate the 
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significance of low levels of arsenic in both the onset and progression of atherosclerosis 
in this animal model. 
 
2.2 Introduction 
Arsenic contamination of ground water is a global problem. In addition to the 
United States, Taiwan, Bangladesh, India, China, Vietnam and Argentina have high 
levels of arsenic in ground water ranging from 50-14,000 ppb (Wang and Wai, 2004). 
Epidemiological evidence suggests that arsenic levels exceeding 20 ppb in drinking water 
are associated with increased mortality from various cardiovascular diseases (Engel and 
Smith, 1994). Atherosclerosis is the most important contributing factor to other 
cardiovascular diseases and can lead to serious clinical manifestations such as ischemic 
heart disease, myocardial infarction and stroke. Epidemiological studies have linked 
arsenic exposure via drinking water to diseases such as carotid atherosclerosis (Wang et 
al., 2002), ischemic heart disease (Tseng et al., 2003) and hypertension (Rahman et al., 
1999). Atherosclerosis is a multifactorial disease. The hallmark of atherosclerosis is 
inflammation, characterized by the increased expression of cell adhesion molecules, 
proinflammatory cytokines and chemokines (Tedgui and Mallat, 2006, Blankenberg et 
al., 2003, Reape and Groot, 1999, Zeitler et al., 1997, Libby, 2002, Lusis, 2000). In 
particular, increased levels of the proinflammatory cytokine, interleukin-6 (IL-6), have 
been observed in patients with acute myocardial infarction (Erren et al., 1999, Ikeda et 
al., 1992), and it has been implicated in smooth muscle cell proliferation, formation of 
atherosclerotic lesions and instability of the atherosclerotic plaques (Ikeda, 2003, Rattazzi 
et al., 2003). Also, elevated levels of soluble vascular cell adhesion molecule-1 (sVCAM-
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1) have been observed in patients with coronary heart disease and myocardial infarction 
(Zeitler et al., 1997), although its pathological role is unclear. 
In addition to the epidemiological evidence, controlled animal studies have 
confirmed the association between arsenic exposure and development of atherosclerosis. 
It has been shown that exposure to 20 and 100 ppm arsenic in drinking water for 24 
weeks accelerates atherogenesis in apolipoprotein E knockout (ApoE-/-) mice 
(Simeonova et al., 2003). Furthermore, we showed that chronic exposure (18 weeks) to 
10 ppm arsenic in drinking water exacerbates atherosclerotic plaque formation in 
apolipoprotein E and low density lipoprotein receptor double knockout (ApoE-/- /LDLr-/-
) mice (Bunderson et al., 2004). The ApoE-/- /LDLr-/- mouse is a well established model 
of human atherosclerosis. Mice are resistant to the development of atherosclerosis, but 
targeted gene deletion of ApoE and LDLr in mice results in hyperlipidemia and 
atherosclerosis that resembles human disease (Ishibashi et al., 1994, Jawein et al., 2004). 
While, the animal studies have helped to clearly establish the link between arsenic 
exposure and atherosclerosis by eliminating the confounding factors that obscure 
epidemiological studies, the temporal effects of arsenic exposure in the development of 
atherosclerosis have not been identified. Also, the effects of arsenic concentrations lower 
than 10 ppm on atherogenesis have yet to be determined. In the present study, we 
investigated the time- and concentration-dependent effects of arsenic on the development 
of atherosclerosis in the ApoE-/- /LDLr-/- mouse.  
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2.3 Materials and Methods 
2.3.1 Experimental animals. ApoE-/- /LDLr-/- mice were obtained from Jackson 
Laboratories (Bar Harbor, ME). All the animals were housed under specific pathogen-
free conditions according to IACUC protocols with 12 h light/dark cycle and controlled 
temperature. The animals receiving arsenic treatment were given either 10 ppm As(III) 
(GFS Chemicals, Columbus, OH) for 5 or 10 weeks or 1, 5 and 10 ppm As(III) for 20 
weeks ad libitum via drinking water. The control group received ddH2O. The mice were 
fed a commercial mouse chow diet. Male and female animals were evenly distributed 
between treatment and control groups and were 4-7 weeks of age at the beginning of the 
study. Mice were weighed at the beginning and termination of the study. 
 
2.3.2 Dissection procedures and quantification of atherosclerotic plaques. At the 
termination of treatments, blood was collected from each animal and the mice were 
perfused with 1% paraformaldehyde/PBS. The dissection of the innominate artery and 
quantification of the atherosclerotic plaques were done as described by Bunderson et al. 
(2004) with slight modifications. Briefly, cross sections of 10 μm thickness were 
obtained from paraffin-embedded innominate arteries of control and As(III)-treated mice. 
To ensure that the majority of plaque expanse was analyzed, the fifth, tenth and fifteenth 
sections of each sample, beginning from the base of the innominate artery, were stained 
with Movat’s pentachrome. The sections were examined using blinded methods. Image 
analysis was done using NIH ImageJ software. 
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2.3.3 Enzyme-linked immunosorbent assay. Blood collected from ApoE-/- /LDLr-/- 
mice treated with 10 ppm As(III) for 10 or 20 weeks was used to analyze serum IL-6 and 
sVCAM-1 levels. Serum was obtained by centrifugation of the blood at 1,600 rpm for 5 
min at 4 0C and was stored at -80 0C until analysis. Serum IL-6 and sVCAM-1 levels 
were analyzed by ELISA kits from BD Biosciences (San Diego, CA) and R&D Systems 
(Minneapolis, MN), respectively, according to the manufacturer’s instructions. 
 
2.3.4 Statistical analysis. Results are presented as mean ± standard error of the mean 
(SEM). Statistical analysis was performed using Student’s t test when comparing two 
groups or Bonferroni method for comparing three groups or more. When using the 
Bonferroni method, the alpha level of each individual test was adjusted downwards to 
ensure that the overall experiment wise-risk remains at 0.05. Statistical analysis was 
performed using GraphPad Prism, version 4.00. Alpha error was set at p<0.05. 
 
2.4 Results and Discussion 
Epidemiological studies have associated arsenic exposure with the development 
of cardiovascular diseases such as carotid atherosclerosis and ischemic heart disease 
(Wang et al., 2002, Tseng et al., 2003). Previous studies, using animal models of 
atherosclerosis, have shown that exposure of mice to 10, 20 and 100 ppm arsenic 
exacerbates the process of atherosclerosis (Bunderson et al., 2004, Simeonova et al., 
2003). This is the first study to show that low and environmentally relevant 
concentrations of arsenic (1 and 5 ppm) significantly increase atherosclerotic plaque 
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formation in the ApoE-/- /LDLr-/- mice. Analysis of the temporal effects of arsenic 
suggests that it may also contribute to the initiation of atherosclerosis. 
The concentration-dependent effects of As(III) in the development of 
atherosclerosis were determined by exposing ApoE-/- /LDLr-/- mice to 1, 5 and 10 ppm 
As(III) in drinking water for 20 weeks (Fig. 6). Atherosclerotic plaque development was 
determined by measuring the percent occlusion of the innominate artery, which is a small 
vessel that connects the aortic arch to the right subclavian and right carotid arteries. 
Development of atherosclerotic lesions in this artery has been shown to progress at a 
highly consistent rate and closely resemble that of human condition, with events such as 
intraplaque hemorrhage and loss of fibrous cap or plaque rupture (Rosenfeld et al., 2000). 
The innominate arteries obtained from mice exposed to 1, 5 and 10 ppm As(III) were 
stained with Movat’s pentachrome (Fig. 6A). The percent occlusion of the innominate 
artery was determined by dividing the plaque area by the lumen area plus the plaque area. 
Histology revealed a significant increase in plaque formation with 1 and 5 ppm As(III) 
treatment compared to the control group (Fig. 6B).  
These concentrations of arsenic are well within the range encountered in the water 
supplies of the aforementioned countries having 0.05-14 ppm of arsenic contamination in 
drinking water (Wang and Wai, 2004). This finding is remarkable when considering that 
the toxicity of arsenic in humans could be much greater than that in mice at equivalent 
concentrations. Mice excrete approximately 90% of ingested arsenic in 2 days, whereas 
the biological half-time of arsenic in humans is on the order of 4 days (Vahter, 2000). 
Therefore, human subjects could be even more susceptible to arsenic-induced 
cardiovascular toxicity.  
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Our lab has previously shown that exposure to 10 ppm As(III) for 18 weeks 
significantly increases atherosclerotic plaque formation in ApoE-/- /LDLr-/- mice 
(Bunderson et al., 2004). In the present study, however, only an increasing trend in 
plaque formation was observed with 10 ppm As(III) treatment for 20 weeks (Fig. 6B) 
along with a significant increase in IL-6 levels (Fig. 8B). Increases in IL-6 levels have 
been strongly correlated with atherosclerotic plaque instability and rupture in human 
subjects (Schieffer et al., 2000) as well as a mouse model (Cheng et al., 2006). IL-6 is an 
important factor for increased plaque vulnerability because it stimulates the matrix 
degrading enzymes such as metalloproteinases (Cheng et al., 2006, Schieffer et al., 2000, 
Lin et al., 2007). In addition, studies have demonstrated the expression of IL-6 in the 
lipid-rich shoulder areas of plaques that are the most vulnerable sites of plaque rupture 
(van der Wal et al., 1994, Schieffer et al., 2000, Cheng et al., 2006). Therefore, it is 
possible that plaque rupture might have contributed to the statistically non-significant 
increase in atherosclerotic plaques observed with 10 ppm As(III) treatment for 20 weeks 
compared to our previous finding at 18 weeks of As(III) treatment (Bunderson et al., 
2004). To ensure that the mice were sufficiently hydrated and healthy, all the animals 
were weighed at the beginning (initial weight) and at the termination (final weight) of the 
study. Final and initial weights were not significantly different between the control group 
and the As(III) treated groups (Table 1). In addition, visual inspection of the animals 
revealed no apparent adverse effects related to As(III) treatment on the general health of 
the animals. 
The temporal effects of As(III) on atherogenesis were determined by exposing the 
ApoE-/- /LDLr-/- mice to 10 ppm As(III) via drinking water for 5 or 10 weeks (Fig. 7). 
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The innominate arteries obtained from mice exposed to As(III) for 5 weeks (Fig. 7A) and 
10 weeks (Fig. 7C) were stained with Movat’s pentachrome. Histology revealed an 
increasing trend in plaque formation with As(III) treatment at 5 weeks (Fig. 7B) and 10 
weeks (Fig. 7D) compared to the control mice. These results suggests that As(III) may 
affect the initiation of atherosclerosis since an increasing trend in plaque formation was 
observed as early as 5 weeks. An initiating event in the development of atherosclerosis is 
increased accumulation of oxidized low density lipoproteins (LDLs) and monocytes 
within the blood vessel intima that leads to the formation of foam cells and ultimately 
culminates with the development of plaques (Lusis, 2000, Libby, 2002). Damage to the 
endothelium can result in increased permeability/passage of oxidized LDLs and 
monocytes across the endothelial monolayer. Consistent with this, we have recently 
documented that arsenic treatment induces intercellular gaps and increases permeability 
in cultured human aortic endothelial cells (Pereira et al., 2007), and in situ arsenic 
treatment has been shown to increase vascular permeability in rodents (Chen et al., 2004, 
Tsai et al., 2005). In addition, IL-6 has been shown to increase endothelial permeability 
(Desai et al., 2002). We observed that with 10 ppm As(III) treatment, serum IL-6 levels 
showed an increasing trend at 10 weeks (Fig. 8A) and a significant increase at the 20 
week time point (Fig. 8B). Therefore, arsenic could potentially affect the initiation of 
atherosclerosis by increasing vascular permeability and the accumulation of oxidized 
LDLs and monocytes within the neo-intima of the blood vessel.  
Surprisingly, a significant decrease was observed in sVCAM-1 levels at both 10 
week (Fig. 9A) and 20 week (Fig. 9B) time points with 10 ppm As(III) treatment. The 
expression of VCAM-1 by endothelial cells is an early event in the development of 
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atherosclerosis (Nakashima et al., 1998). The role of VCAM-1 expressed by endothelial 
cells in atherogenesis is well characterized and is known to mediate transmigration of 
monocytes into the blood vessel intima (Cybulsky et al., 2001, Nakashima et al., 1998, 
Lusis, 2000). The soluble form of VCAM-1 has been proposed to be a prognostic factor 
in clinical manifestations such as myocardial infarction, coronary artery disease and 
unstable angina. However, contradictory results have been documented regarding the 
correlation of sVCAM-1 with cardiovascular events. Rohde et al. (1998) and Zeitler et al. 
(1997) demonstrated a correlation between increased serum levels of sVCAM-1 with 
carotid atherosclerosis and myocardial infarction, whereas Hwang et al. (1997) and Saku 
et al. (1999) found no such correlation. Furthermore, the clinical relevance of the 
sVCAM-1 is unclear (Blakenberg et al., 2003, Lind, 2003). The genesis of soluble form 
of VCAM-1 is also not certain. The most widely accepted theory is the proteolytic 
cleavage of cell surface expressed VCAM-1 molecule by an unidentified metalloprotease 
(Leca et al., 1995) and the relation between cellular expression and amount of soluble 
forms has yet to be elucidated (Blakenberg et al., 2003). This study does not suggest that 
there is reduced expression of endothelial VCAM-1. One possible interpretation for the 
reduced sVCAM-1 is that the increased interaction of the leukocytes with endothelial 
VCAM-1 may inhibit the proteolytic cleavage. Another possibility is increased clearance 
of these plasma proteins, although the mechanism of clearance or catabolism remains 
unknown. As mentioned above, it might also be possible that arsenic exacerbates the 
process of atherosclerosis by damaging the endothelial monolayer and not by modulating 
all of the classical mediators. 
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Atherosclerosis is a multifactorial disease with complex interplay between various 
signaling pathways and inflammatory mediators. Arsenic is a versatile molecule, and 
several mechanisms have been proposed by which it might modulate vascular 
homeostasis and influence the development of atherosclerosis (reviewed in Navas-Acien 
et al., 2005). Therefore, it is possible that arsenic affects atherogenesis by triggering 
multiple mediators. In summary, this study showed that environmentally relevant 
concentrations of arsenic induce significant increases in atherosclerotic plaque formation 
in the ApoE-/- /LDLr-/- mouse. Furthermore, the process of atherosclerosis is plausibly 
initiated or accelerated by arsenic at an early stage. Additional mechanistic studies are 
needed to elucidate how arsenic contributes to the onset and progression of 
atherosclerosis. 
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2.5 Figures 
Fig. 6. Concentration-dependent effect of As(III) in the development of 
atherosclerosis 
 
 
A. 
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Fig. 6. Concentration-dependent effect of As(III) in the development of atherosclerosis. 
ApoE-/- /LDLr-/- mice were given either ddH2O (control) or 1, 5 and 10 ppm As(III) in 
drinking water for 20 weeks and the concentration-dependent effects of As(III) in the 
development of atherosclerotic plaque within the innominate arteries were analyzed (A); 
magnification=10X. Percent occlusion of the innominate arteries was analyzed (B) with 
n=10-19 mice per group and the treatment groups marked with asterisk were significantly 
different from the control (*, p<0.01). 
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Fig. 7. Temporal effect of As(III) in the development of atherosclerosis 
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Fig. 7. Temporal effect of As(III) in the development of atherosclerosis. ApoE-/- /LDLr-
/- mice were given either ddH2O (control) or 10 ppm As(III) in drinking water and the 
temporal effects of As(III) in the development of atherosclerotic plaques within the 
innominate arteries were analyzed at 5 week (A) or 10 week (C) time points; 
magnification=10X. Percent occlusion of the innominate arteries was analyzed at 5 weeks 
(B) with 11-14 mice per group and 10 weeks (D) with 7-12 mice per group.  
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Fig. 8. Effect of As(III) treatment on serum IL-6 levels 
 
A. 
 
 
 
B. 
 
 
 
Fig. 8. Effect of As(III) treatment on serum IL-6 levels. IL-6 levels were measured by 
ELISA in the serum of ApoE-/- /LDLr-/- mice given either ddH2O (control) or 10 ppm 
As(III) for (A) 10 weeks or (B) 20 weeks (n=6-7 mice per group). Treatment group 
marked with asterisk was significantly different from the respective control (*, p<0.05).  
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Fig. 9. Effect of As(III) treatment on serum levels of sVCAM-1 
 
 
 
A. 
 
 
 
B. 
 
 
 
 
Fig. 9. Effect of As(III) treatment on serum levels of sVCAM-1. sVCAM-1 levels were 
measured by ELISA in the serum of ApoE-/- /LDLr-/- mice given either ddH2O (control) 
or 10 ppm As(III) for (A) 10 weeks or (B) 20 weeks (n=7 mice per group). Treatment 
group marked with asterisk were significantly different from the respective control (*, 
p<0.05). 
 
 
 
 
 74
 
Table 1. Body weight of mice exposed to As(III) for 20 weeks.  
 
 Initial weight (g) Final weight (g) Difference (g) 
Control 17.59 ± 0.44 19.93 ± 0.43 2.35 ± 0.27 
1 ppm As(III) 19.54 ± 0.35 21.3 ± 0.37 1.76 ± 0.18 
5 ppm As(III) 17.61 ± 0.59 20.08 ± 0.56 2.47 ± 0.16 
10 ppm As(III) 20.91 ± 0.60 23.04 ± 0.63 2.14 ± 0.20 
Each value represents mean ± SEM; no significant differences observed between groups. 
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Chapter 3 
Activation of Protein Kinase C and Disruption of Endothelial 
Monolayer Integrity by Sodium Arsenite 
 
3.1 Abstract 
The endothelium maintains a semipermeable barrier between the blood and vessel 
wall. The objective of the present study was to determine whether arsenic treatment 
induces activation of protein kinase C (PKC) isoforms, α and β, by generation of the 
reactive nitrogen species, peroxynitrite, and thereby causes endothelial disruption. 
Human aortic endothelial cells (HAECs) were exposed to 1, 5 and 10 μM sodium arsenite 
[As(III)] for 1, 6, 12 and 24 h. Western blotting revealed that As(III) treatment induced a 
concentration-dependent increase in activation of PKCα with no change in PKCβ levels. 
The activation of PKCα was found to be calcium-dependent. Peroxynitrite formation was 
not observed with As(III) treatment. Endothelial barrier integrity is maintained by 
proteins of the adherens junction, vascular endothelial (VE)-cadherin and β-catenin, and 
their association with the actin cytoskeleton. Immunofluorescence studies revealed 
reorganization of actin filaments into stress fibers and non-uniform staining of VE-
cadherin and β-catenin at cell-cell junctions that were concentration- and time-dependent. 
Intercellular gaps were observed with a measured increase in endothelial permeability. In 
addition, a concentration-dependent increase in tyrosine phosphorylation of β-catenin was 
detected by Western blotting. Inhibition of PKCα using the classical PKC inhibitor, Gö 
6979, restored VE-cadherin and β-catenin staining at cell-cell junctions and abolished the 
As(III) induced formation of intercellular gaps and actin stress fibers. Endothelial 
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permeability and tyrosine phosphorylation of β-catenin were also reduced to basal levels. 
These results suggest that As(III) induces activation of PKCα, which leads to increased 
tyrosine phosphorylation of β-catenin and formation of actin stress fibers downstream of 
PKCα activation. Phosphorylation of β-catenin plausibly severs the association of VE-
cadherin and β-catenin, which along with formation of actin stress fibers, results in 
intercellular gap formation and increased endothelial permeability. As(III)-induced loss 
of endothelial monolayer integrity may contribute to the development of atherosclerosis 
by accelerating the accumulation of oxidized low density lipoproteins and monocytes 
within the blood vessel intima. 
 
3.2 Introduction 
Arsenic, an element present in the earth’s crust, has been widely distributed in the 
environment by human activities such as mining, smelting, pesticide application and 
manufacturing and use of products such as wood preservatives and dyes. Epidemiological 
studies analyzing the correlation between cardiovascular diseases and arsenic exposure 
have linked arsenic to atherosclerosis (Wang et al., 2002), ischemic heart disease (Tseng 
et al., 2003) and hypertension (Rahman et al., 1999). Drinking water is a significant 
source of arsenic exposure to humans. Using mouse models of atherosclerosis, we and 
others have demonstrated that chronic exposure to arsenic through drinking water 
exacerbates atherosclerotic plaque formation (Bunderson et al., 2004, Simeonova et al., 
2003). Atherosclerosis can lead to serious clinical manifestations such as heart attack and 
stroke. 
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 Arsenic has been shown to generate reactive oxygen species such as superoxide 
anion and hydrogen peroxide (Barchowsky et al., 1999a) in porcine aortic endothelial 
cells and reactive nitrogen species such as nitric oxide and peroxynitrite in bovine aortic 
endothelial cells (Bunderson et al., 2002, Lynn et al., 1998, Liu and Jan, 2000). 
Peroxynitrite is a strong oxidizing and nitrating molecule formed by the rapid reaction of 
superoxide with nitric oxide. Peroxynitrite has been reported to interfere with cellular 
processes and signal transduction pathways by oxidation as well as nitration of proteins 
(Klotz et al., 2002). Amino acids such as cysteine, tyrosine, methionine and tryptophan 
are known to be modified by peroxynitrite via oxidation or nitration (Pryor and 
Squadrito, 1995, Radi et al., 2001, Beckman, 1996). In particular, 3-nitrotyrosine is a 
stable product that is formed by the attack of peroxynitrite on protein tyrosine residues. 
The detection of 3-nitrotyrosine in biological samples has been used as a marker for the 
presence of peroxynitrite (Ischiropoulos, 1998, Beckman et al., 1994, Beckman and 
Koppenol, 1996, Beckman, 1996). 
 There are numerous regulatory points in the vascular system that may be 
disrupted and lead to atherogenesis. The integrity of the vascular endothelium is 
maintained by proteins of the adherens junctions that includes the transmembrane protein 
vascular endothelial (VE)-cadherin linked to the cytoplasmic protein β-catenin, which in 
turn is linked to the actin cytoskeleton through α-catenin (Ivanov et al., 2001). This 
association is critical to maintaining cell-cell adhesion and structural integrity. The 
tyrosine phosphorylation of adherens junction proteins can alter their interaction with 
each other and the cytoskeleton. Endogenous mediators such as histamine have been 
shown to increase tyrosine phosphorylation of both β-catenin and VE-cadherin, resulting 
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in dissociation of VE-cadherin from the actin cytoskeleton with a subsequent increase in 
vascular permeability (Andriopoulou et al., 1999). The tyrosine phosphorylation of β-
catenin has been shown to cause a fivefold reduction in its affinity for E-cadherin (Lilien 
and Balsamo, 2005, Roura et al., 1999). Accordingly, vascular endothelial growth factor 
(VEGF) induced tyrosine phosphorylation of VE-cadherin and β-catenin has been 
implicated in the loosening of cell-cell contacts and increased vascular permeability 
(Esser et al., 1998).  
The association of cadherin-catenin complex with the actin cytoskeleton is also 
very important for maintaining junctional stability. Reorganization of the actin filaments 
into stress fibers can compromise the stability of the endothelial monolayer. Stress fibers 
consist of proteins such as myosin, tropomyosin and α-actinin intermittently associated 
with the actin filaments (Byers et al., 1984). Stress fibers are contractile elements and 
have been shown to develop in vivo during endothelial cell adaptation to unfavorable or 
pathological situations such as atherosclerosis and hypertension (White et al., 1983, 
Guyton et al., 1989, Colangelo et al., 1998). It has been observed that the 
apolipoprotein(a) component of lipoprotein(a), a risk factor for atherosclerotic disorders, 
induces stress fiber formation and VE-cadherin dispersion accompanied by cell 
retraction, intercellular gap formation and increased endothelial permeability (Pellegrino 
et al., 2004). Thus, development of stress fibers in endothelial cells adversely affects 
monolayer integrity. Treatment with peroxynitrite or the peroxynitrite donor, 3-
morpholinosydnonimine hydrochloride (SIN-1), has been shown to induce actin stress 
fibers and nitration of tyrosine residues on actin and β-catenin in porcine aortic 
endothelial cells with an increase in permeability (Knepler et al., 2001). Nitration of these 
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proteins was proposed to be the cause of endothelial disruption. However, the effects of 
arsenic on the proteins involved in maintaining endothelial monolayer integrity remain 
unknown. 
 Several signaling intermediates have been implicated in the regulation of 
endothelial barrier function. In particular, the various protein kinase C (PKC) isotypes 
have a host of cellular substrates and are involved in numerous biological processes. 
PKCs are serine/threonine kinases and have been grouped into 3 subfamilies: classical, 
novel and atypical PKCs (Newton, 2001). The classical PKCs (cPKC), which consists of 
α, β and γ subtypes, are activated in calcium (Ca2+)-dependent manner and require 
diacylglycerol and phosphatidylserine. The PKCβ gene is alternatively spliced into 
PKCβ1 and β2 isoforms that differ by 2 amino acids in the C-terminal kinase domain. The 
PKCβ1 isoform consists of 50 residues and the β2 isoform has 52 residues (Kawakami et 
al., 2002). Among the cPKCs, endothelial cells express α and β isotypes (Mattila et al., 
1994). The cPKCs have been implicated in the modulation of endothelial barrier function 
(Yuan, 2003). Activation of PKCα by thrombin has been shown to induce actin stress 
fibers and increase endothelial permeability (Sandoval et al., 2001). VEGF has been 
shown to activate PKCα, PKCβ1 and β2, and inhibition of the PKCβ isoforms was 
demonstrated to inhibit the dissociation of β-catenin from VE-cadherin and reduce 
endothelial permeability observed with PKC activation (Wang et al., 2004). Nagpala et 
al. (1996) have demonstrated that overexpression of PKCβ1 in endothelial cells increases 
permeability when stimulated with phorbol ester. Conflicting data exist regarding the 
effects of arsenic on the modulation of intracellular Ca2+ levels and cPKCs; effects that 
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are dependent on the cell line studied and the duration of arsenic treatment (Chen et al., 
2000, Liu and Huang, 1997). 
 Peroxynitrite has been implicated in the modulation of cPKC activity. It has been 
shown that treatment of endothelial cells with peroxynitrite results in an increase in Ca2+-
dependent PKCα activity that was inhibited by the intracellular Ca2+ chelator, BAPTA-
AM, and the cPKC inhibitor, Gö 6976. Peroxynitrite treatment also induced tyrosine 
nitration of PKCα (Chakraborti et al., 2005). Conversely, peroxynitrite treatment has 
been shown to nitrate tyrosine residues and inactivate PKCα and β isoforms in 
hippocampal homogenates and rat brain purified PKC (Knapp et al., 2001). The effect of 
arsenic-induced peroxynitrite formation in the modulation of cPKC activation remains 
unknown. 
 Various mechanisms for arsenic-induced atherosclerosis have been proposed 
including activation of the endothelium that is characterized by up-regulation of adhesion 
molecules and inflammatory mediators (Simeonova and Luster, 2004). In particular, in 
situ arsenic exposure through intradermal injections on the dorsal surface of rats has been 
shown to induce vascular permeability (Chen et al., 2004). However, the mechanism of 
increased vascular permeability remains unknown. The endothelium maintains a 
semipermeable barrier and damage to the endothelial lining can result in increased 
permeability. This could lead to subsequent recruitment and migration of monocytes and 
oxidized low density lipoproteins (oxLDL) into the intima of the blood vessel, thereby 
promoting the development of atherosclerotic lesions. Hence, the objective of this study 
was to determine the effects of arsenic on endothelial barrier integrity and characterize 
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the pathways for arsenic-induced increases in vascular permeability. We also analyzed 
whether the effects of arsenic were mediated through formation of peroxynitrite. 
 
3.3 Materials and Methods 
3.3.1 Cell culture. Human aortic endothelial cells (HAECs) were purchased from 
Cambrex Bio Science (Walkersville, MD) and were grown in the supplier’s formulated 
medium: EBM-2 medium supplemented with EGM-2 SingleQuots (0.04% 
hydrocortisone, 0.4% hFGF-B, 2% FBS and 0.1% each of VEGF, R3-IGF-1, ascorbic 
acid, heparin, hEGF and GA-1000). Bovine aortic endothelial cells (BAECs) were 
provided by Dr. J. Douglas Coffin of The University of Montana, Missoula and were 
originally a gift from Dr. Steve Schwartz of The University of Washington. Cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) with penicillin/streptomycin and 
L-glutamine, and supplemented with 15% FBS (Mediatech, Inc., Herndon, VA). The 
HAECs and BAECs were incubated at 37 0C under a humidified atmosphere containing 
5% CO2. Cells were used between passages 2 and 10.  
 
3.3.2 Cell viability assay. The viability of HAECs was determined using the 3-(4,5-
dimethythiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay described by 
Bunderson et al. (2002) with some modifications. HAECs were seeded at a density of 
1x104 cells/well in 96-well plates. At 24 h post seeding, cells were treated with 0.5, 1, 
2.5, 5, 10, 25, 50, 100, 250 or 500 μM concentrations of sodium arsenite [As(III)] (GFS 
Chemicals, Columbus, OH) for 12, 24 and 48 h. The treatment solutions were removed 
and replaced with medium alone for 24 h. MTT/medium solution (50 μg) was added to 
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each well and cells were incubated for another 4 h. The MTT/medium solution was 
carefully removed and the formazan crystals were dissolved in 100 μl DMSO/well. 
Absorbance was determined using the VersaMax microplate reader (Molecular Devices 
Corporation, Sunnyvale, CA) at 560 nm. The effect of Gö 6976 (Calbiochem, San Diego, 
CA), nitro-L-arginine methyl ester (L-NAME) (Sigma-Aldrich, Saint Louis, MO) and 
5,10,15,20-Tetrakis-[4-sulfonatophenyl]-porphyrinato-iron[III], Chloride (FeTPPS) 
(Calbiochem, San Diego, CA) on cell viability for 24 h was also determined. 
 
3.3.3 Detection of Peroxynitrite. Generation of peroxynitrite with As(III) treatment 
was determined in HAECs and BAECs by analyzing nitrotyrosine formation. Cells were 
grown on 18-mm round coverslips inserted into 12-well plates. For HAECs 0.1 mg/ml 
solution of Poly-D-Lysine hydrobromide (Sigma-Aldrich, Saint Louis, MO) was used to 
coat the coverslips. HAECs and BAECs were seeded at a density of 2x105-3x105 
cells/well in 12-well plates and were grown to confluence for 48-72 h. Cells were then 
treated with As(III) for specified time periods. Cells were fixed with 1% 
paraformaldehyde/phosphate-buffered saline (PBS) for 30 min at room temperature (RT), 
permeabilized using 0.1% saponin solution/ PBS for 10 min at RT and then blocked with 
5% goat serum/PBS (Sigma-Aldrich, Saint Louis, MO) for 30 min at RT. Cells were then 
incubated with 20 μg/ml rabbit anti-nitrotyrosine polyclonal antibody for 24 h at 4 0C 
followed by incubation with 10 μg/ml Alexa Fluor 594-conjugated goat anti-rabbit 
secondary antibody (Molecular Probes, Inc. Eugene, OR) for 1 h at RT in the dark. Cells 
were counterstained with Hoechst 33342 stain for 5 min at RT, coverslipped with 
Fluorosave (EMD Biosciences, San Diego, CA) and stored in the dark until imaged. 
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Fluorescence was quantitated using a Laser Scanning Cytometer (CompuCyte 
Corporation, Cambridge, MA).  
Generation of peroxynitrite with As(III) treatment was also determined in HAECs 
by analyzing the oxidation of hydroethidine to its fluorescent form ethidium (Zhao et al., 
2005, Zhao et al., 2003). HAECs were grown in 24-well plates coated with 0.1 mg/ml 
solution of Poly-D-Lysine hydrobromide. Cells were seeded at a density of 1x105 
cells/well and grown to confluence for 48-72 h. Cells were incubated with 20 μM 
hydroethidine/PBS for 30 min at 37 0C. PBS was supplemented with 1 mM CaCl2, 0.5 
mM MgCl2 and 2% fetal bovine serum and was used for rinsing cells and preparing all 
the solutions for this experiment. Cells were rinsed twice with PBS and then incubated 
with As(III)/PBS with or without the peroxynitrite decomposition catalyst, FeTPPS, for 1 
h at 37 0C. The total volume of solution in each well was 1 ml at all times except during 
fluorescence measurement when the volume was reduced to 200 μl. Fluorescence 
intensity was analyzed using the SpectraMax GeminiXS fluorescence plate reader 
(Molecular Devices Corporation, Sunnyvale, CA) at 510 nm excitation and 590 nm 
emission wavelengths (Zhao et al., 2005, Zhao et al., 2003). 
 
3.3.4 Immunofluorescence. HAECs were grown on 18-mm round coverslips inserted 
into 12-well plates and coated with 0.1 mg/ml solution of Poly-D-Lysine hydrobromide. 
HAECs were seeded at a density of 2x105-3x105 cells/well and were grown to confluence 
for 48-72 h. Cells were treated with As(III) and the cPKC inhibitor, Gö 6976, was added 
1 h prior to and during the As(III) treatment wherever applicable. Cells were fixed with 
1% paraformaldehyde/PBS for 30 min at RT, permeabilized using 0.1% saponin/PBS for 
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10 min at RT and then blocked with 5% goat serum/PBS for 30 min at RT. Cells were 
then incubated with either 2 μg/ml rabbit anti-VE-cadherin polyclonal antibody (Cayman 
Chemicals, Ann Arbor, MI) or 2 μg/ml rabbit anti-β-catenin polyclonal antibody 
(Cayman Chemicals, Ann Arbor, MI) or 0.24 μg/ml rabbit polyclonal antibody against 
cleaved caspase-3 (Cell Signaling Technology, Danvers, MA) in PBS for 2 h at RT or 24 
h at 4 0C followed by incubation with 10 μg/ml Alexa Fluor 488-conjugated goat anti-
rabbit secondary antibody (Molecular Probes, Inc. Eugene, OR) for 1 h at RT in the dark. 
For detection of stress fibers, HAECs were incubated with 16.5 nM Alexa Fluor 568-
conjugated phalloidin (Molecular Probes, Inc. Eugene, OR) for 25 min at RT in the dark. 
Cells were counterstained with Hoechst 33342 stain for 5 min at RT, coverslipped with 
Fluorosave and stored in the dark until imaged. Slides were photographed with a Nikon 
Digital Eclipse DXM1200 camera attached to a Nikon E-800 microscope using a 60X oil 
immersion lens.  
 
3.3.5 Permeability Assay. HAECs (1x105-1.5x105) were seeded on 0.4-μm pore 
polyester membrane transwell inserts (Corning Incorporated, Acton, MA) coated with 0.1 
mg/ml solution of Poly-D-Lysine hydrobromide in 12-well plates. Cells were grown to 
confluence for 48-72 h. The volume of medium in the Transwell was 500 μl with 1.5 ml 
in the plate well at all times. The As(III) treatments were added to the Transwells and the 
cPKC inhibitor, Gö 6976, was added 1 h prior to and during the As(III) treatment 
wherever applicable. At the final 1 h of respective treatments, fluorescein isothiocyanate 
(FITC)-labeled dextran (average molecular weight 40,000, final concentration of 1 
mg/ml; Sigma-Aldrich, Saint Louis, MO) was added to each Transwell including control 
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wells. After completion of the treatment period, the fluorescence intensity of the medium 
in the plate well was analyzed using a SpectraMax GeminiXS fluorescence plate reader. 
For each sample, 5 aliquots of 200 μl each were analyzed using an excitation wavelength 
of 490 nm and emission wavelength of 520 nm.  
 
3.3.6 Immunoprecipitation of VE-cadherin and β-catenin. To detect tyrosine 
phosphorylation and tyrosine nitration of VE-cadherin and β-catenin, the proteins were 
first immunoprecipitated. HAECs were seeded at a density of 7.5x105 cells/25 cm2 cell 
culture flask and allowed to reach confluence for 48-72 h. Confluent cells were treated 
with As(III) and the cPKC inhibitor, Gö 6976 was added 1 h prior to and during As(III) 
treatment wherever applicable. After completion of treatment, cells were rinsed with cold 
PBS containing phosphatase inhibitors (1 mM β-glycerophosphate, 1 mM Sodium 
pyrophosphate and 2.5 mM Sodium orthovanadate). The sodium orthovanadate was 
activated for maximal inhibition of protein tyrosine phosphatases (activation method 
obtained from the list of protocols provided by Upstate Cell Signaling Solutions). Cells 
were harvested using cold 1X RIPA buffer (20 mM Tris, pH 7.5, 5 mM EDTA, 2 mM 
EGTA, 1% Igepal, 0.1% SDS and 0.5% Deoxycholic acid) containing protease inhibitors 
(Complete protease inhibitor cocktail tablet; Roche Diagnostics, Indianapolis, IN) and 
phosphatase inhibitors. Cells were homogenized by sonication and centrifuged at 10,000 
rpm for 15 min at 4 0C. The supernatant was sequentially incubated with 5 μg/ml each of 
mouse anti-VE-cadherin monoclonal antibody followed by mouse anti-β-catenin 
monoclonal antibody (Abcam, Cambridge, MA) for 24 h at 4 0C. Immune complexes 
were precipitated using immobilized protein G (Pierce, Rockford, IL). After incubation 
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for 2 h at 4 0C, the agarose bound immune complexes were washed three times with cold 
1X RIPA buffer containing protease and phosphatase inhibitors and then heated at 70 0C 
for 10 min in 1X solution of reducing agent and sample buffer (Invitrogen Life 
Technologies, Carlsbad, CA).  
 
3.3.7 Western blot analysis for VE-cadherin and β-catenin. The tyrosine 
phosphorylation and tyrosine nitration of VE-cadherin and β-catenin was analyzed by 
immunoprecipitation followed by Western blot. The immunoprecipitated proteins were 
resolved using 4-12% NuPAGE Novex Bis-Tris gel (Invitrogen Life Technologies, 
Carlsbad, CA), transferred to a polyvinylidenedifluoride (PVDF) membrane, blocked 
with 5% BSA/TBST (TBST: 1.57 gm/l Tris HCl (pH=8), 8.76 gm/l NaCl, 500 μl/l Tween 
20) for 1 h at RT and incubated with 2 μg/ml mouse anti-phosphotyrosine monoclonal 
antibody (BD Transduction Laboratories, San Jose, CA) or 2 μg/ml rabbit anti-
nitrotyrosine polyclonal antibody overnight at 4 0C in 1% BSA/TBST solution. This was 
followed by incubation of the membrane with 1 μg/ml peroxidase labeled horse anti-
mouse or 5 μg/ml goat anti-rabbit secondary antibody (Vector laboratories Inc., 
Burlingame, CA) for 1 h at RT in 1% BSA/TBST solution. The protein bands were 
visualized by ECL Western blot detection system (Amersham, Buckinghamshire, 
England). To quantitate tyrosine phosphorylation and tyrosine nitration, the total protein 
content of immunoprecipitated VE-cadherin and β-catenin was determined as follows. 
After analysis of phosphotyrosine and nitrotyrosine content, the membranes were 
stripped at 60 0C for 1 h using stripping buffer (100 mM β-mercaptoethanol, 2% SDS and 
62.5 mM Tris HCL, pH 6.8), blocked with 5% non-fat milk/TBST for 1 h at RT and 
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reprobed for VE-cadherin and β-catenin protein using 1.25 μg/ml rabbit anti-VE-cadherin 
and 1 μg/ml rabbit anti-β-catenin polyclonal antibody (Cayman Chemicals, Ann Arbor, 
MI) overnight at 4 0C in 0.4% non-fat milk/TBST. This was followed by incubation with 
5 μg/ml peroxidase labeled goat anti-rabbit secondary antibody for 1 h at RT in 0.4% 
non-fat milk/TBST, and the protein bands were visualized as previously described.  
 To determine the protein content of VE-cadherin without immunoprecipitation, 
cells were rinsed with PBS and harvested with 1X RIPA buffer containing protease 
inhibitors. Cells were homogenized with 18- and 25-gauge needles and boiled for 10 min. 
Protein concentrations were determined by using the Bradford protein assay (Biorad, 
Hercules, CA). The proteins were resolved using 4-12% NuPAGE Novex Bis-Tris gel, 
transferred to PVDF membrane, blocked with 5% non-fat milk/TBST for 2 h at RT and 
probed for VE-cadherin protein using 1.25 μg/ml rabbit anti-VE-cadherin polyclonal 
antibody for 2 h at RT or overnight at 4 0C in 0.4% non-fat milk/TBST. This was 
followed by incubation with 5 μg/ml peroxidase labeled goat anti-rabbit secondary 
antibody for 1 h at RT in 0.4% non-fat milk/TBST. The protein bands were visualized by 
ECL Western blot detection system. Protein loading was normalized using β-actin as 
loading control. β-actin protein was detected using 0.24 μg/ml mouse anti-β-actin 
monoclonal antibody (Abcam, Cambridge, MA) and 1 μg/ml peroxidase labeled horse 
anti-mouse as the secondary antibody. 
 
3.3.8 Western blot analysis for PKCα and β1. HAECs were seeded at a density of 
7.5x105 cells in 25 or 75 cm2 cell culture flasks and after 3-5 days, confluent cells were 
treated with As(III). Treatments of FeTPPS, L-NAME, Gö 6976 and BAPTA-AM (1,2-
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bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester) were applied 
with or without As(III) wherever applicable. Cells were rinsed with cold PBS, harvested 
using homogenizing buffer (50 mM Tris HCl, pH 7.5, 1 mM EDTA and protease 
inhibitors) and sonicated. To separate the membrane and cytosolic fractions, the lysates 
were centrifuged at 100,000x g for 1 h at 4 0C. The supernatant was collected as the 
cytosolic fraction. The pellet was dissolved in 1X RIPA buffer containing protease 
inhibitors, sonicated and centrifuged again at 100,000x g for 1 h at 4 0C. The supernatant 
was the membrane fraction. Protein concentrations were determined by using the 
Bradford protein assay. The proteins were resolved using 4-12% NuPAGE Novex Bis-
Tris gels. To detect good quality protein bands, different amounts of cytosolic and 
membrane fraction proteins were loaded; 10-20 μg protein for the cytosolic fraction and 
40-55 μg protein for the membrane fraction. After separation, the proteins were 
transferred to PVDF membranes, blocked with 5% non-fat milk/TBST for 1 h at RT and 
probed for PKCα or PKCβ1 protein using 0.4 μg/ml mouse anti-PKCα or mouse anti-
PKCβ1 monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight 
at 4 0C in 0.4% non-fat milk/TBST. This was followed by incubation with 1 μg/ml horse 
anti-mouse secondary antibody conjugated with horseradish peroxidase for 1 h at RT in 
0.4% non-fat milk/TBST. Protein bands were visualized by ECL Western blot detection 
system. Na+/K+ ATPase was used as loading control for the membrane fraction using 0.4 
μg/ml mouse anti-Na+/K+ ATPase monoclonal antibody (Upstate Cell Signaling 
Solutions, Lake placid, NY) and GAPDH was used as loading control for the cytosolic 
fraction using 1 μg/ml mouse anti-GAPDH monoclonal antibody (Chemicon 
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International, Inc., Temecula, CA). In both cases, 1 μg/ml horse anti-mouse secondary 
antibody was used.  
 
3.3.9 Statistical analysis. Results are presented as means ± standard error of the mean 
(SEM). When required, data was normalized with its respective control in order to 
exclude differences in background conditions. Statistical analysis was performed using 
Student’s t test when comparing two groups or Bonferroni method for comparing three 
groups or more. When using the Bonferroni method, the alpha level of each individual 
test was adjusted downwards to ensure that the overall experiment wise-risk remains at 
0.05. Statistical analysis was performed using GraphPad Prism, version 4.00. Alpha error 
was set at p<0.05. 
 
3.4 Results 
3.4.1 Cell viability after As(III) treatment  
Cell viability was assessed using the MTT assay that is based on the reduction of yellow 
MTT to purple formazan by metabolically active cells. The effect of 0.5, 1, 2.5, 5, 10, 25, 
50, 100, 250 or 500 μM concentrations of As(III) on HAEC viability was determined at 
12, 24 and 48 h. The IC50 and threshold values are represented in Table. 2. IC50 
represents the concentration at which cell viability was reduced by 50% and threshold 
value represents the concentration at which no toxicity was observed at that particular 
time point. A maximum concentration of 10 μM As(III) was used in all the experiments 
for a time period not exceeding 24 h. No toxicity was observed at the concentration and 
time points used in our experiments. 
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3.4.2 Effect of As(III) on peroxynitrite formation  
Peroxynitrite induces nitration of tyrosine residues in proteins resulting in the formation 
of 3-nitrotyrosine that is a stable adduct (Ischiropoulos, 1998, Beckman et al., 1994, 
Beckman and Koppenol, 1996, Beckman, 1996). Peroxynitrite generation in HAECs with 
1, 5 and 10 μM As(III) treatment was analyzed at 1, 6 and 24-h time points by 
immunofluorescence detection of 3-nitrotyrosine. No changes in 3-nitrotyrosine levels 
were observed in the HAECs. The data for the 24-h time point has been shown (Fig. 
10A). However, a significant increase in 3-nitrotyrosine was observed in BAECs treated 
with 10 μM As(III) for 24 h (Fig. 10B).  
Our laboratory has previously shown that 1 h As(III) treatment induces 
peroxynitrite formation in BAECs using the hydroethidine assay (Bunderson et al., 2002). 
Hydroethidine is oxidized to the fluorescent product ethidium with reactive species such 
as hydrogen peroxide, hydroxyl radical and peroxynitrite. Reaction of hydroethidine with 
intracellular superoxide results in the formation of 2-hydroxyethidium, which is very 
distinct from ethidium (Zhao et al., 2005, Zhao et al., 2003). Treatment of HAECs with 1, 
5 and 10 μM As(III) for 1 h showed an increasing trend in peroxynitrite formation with 
10 μM As(III), but it was not statistically significant. Exposure of cells to the 
peroxynitrite decomposition catalyst, FeTPPS (10 μM), during 10 μM As(III) treatment 
reduced the peroxynitrite formed to basal levels. No change was observed with 1 and 5 
μM As(III) treatment (Fig. 10C). The effect of FeTPPS on cell viability was assessed 
using the MTT assay and no loss of viability was observed at concentrations 1 μM-50 μM 
up to 24 h (data not shown). 
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3.4.3 Dose response of HAECs to cPKC inhibitor Gö 6976 
The indolocarbazole Gö 6976 has been shown to be a potent and selective inhibitor of 
cPKCs via interference with binding of ATP to the kinase (Martiny-Baron et al., 1993). 
Preliminary experiments using HAECs at 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h and 6 h 
revealed that 10 μM As(III) induces intercellular gaps beginning at 1 h of treatment that 
were identified by immunofluorescence staining of VE-cadherin. To determine the 
effective concentration of Gö 6976 to be used in our experiments, cells were exposed to 
10 μM As(III) alone or to 10 nM, 50 nM, 100 nM, 250 nM, 500 nM and 1 μM Gö 6976 
in the presence of 10 μM As(III) as depicted in Fig. 11. The duration of As(III) treatment 
was 1 h and the respective Gö 6976 treatments were applied 1 h prior to and during 
As(III) treatment. As analyzed by immunofluorescence staining of VE-cadherin, 250 nM-
1 μM concentrations of Gö 6976 (Fig. 11F-H) were able to inhibit the As(III) induced 
gap formation. Therefore, in all the further experiments, 250 nM Gö 6976 was used to 
inhibit the activity of cPKCs. Also, the effect of Gö 6976 on cell viability was assessed 
using the MTT assay and no loss of viability was observed at concentrations 10 nM-500 
nM up to 24 h (data not shown). 
 
3.4.4 Effect of As(III) on the activation of PKCα 
The translocation of PKC from cytosol to the membrane is an important step in its 
activation process (Newton, 2001). Therefore, the effect of As(III) on the activation of 
cPKCs in HAECs was analyzed by separation of the cytosolic and membrane fractions 
and determining the protein content in each fraction by Western blotting technique. 
Preliminary experiments showed that 10 μM As(III) treatment induced translocation of 
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PKCα from the cytosolic fraction to the membrane fraction at 1 h, but not with 15 min 
As(III) treatment. Also, serum starvation of cells (only 1% serum in medium) for 24 h 
followed by 1 h of 10 μM As(III) treatment showed a similar increase in PKCα levels in 
the membrane fraction as with 10 μM As(III) treatment without serum starvation. Hence, 
activation of cPKCs was analyzed at 1 h of As(III) treatment using medium containing 
serum, which is the normal environment for endothelial cells. As(III) induced damage to 
the endothelial monolayer was also observed starting at the 1-h time point. Therefore, 
cells were exposed to 1, 5 and 10 μM As(III) and cPKC activation was analyzed at the 1-
h time point (Fig. 12). Treatment with 5 and 10 μM As(III) induced a significant increase 
in PKCα activation as determined by quantifying the protein content in the membrane 
fraction (Figs. 12A and B). No change was observed with 1 μM As(III) treatment. In the 
cytosolic fraction, a decrease in the PKCα content was observed with increasing As(III) 
concentration indicative of PKCα translocation from the cytosol to the membrane (Figs. 
12C and D). Treatment of the cells with 250 nM Gö 6976 for 1 h or with 20 μM BAPTA-
AM for 30 min, prior to and during 10 μM As(III) treatment inhibited the PKCα 
activation as analyzed in the membrane fraction (Figs. 12E and F). The acetoxymethyl 
(AM) ester derivatives are cell permeable and hence BAPTA-AM was used as an 
intracellular Ca2+ chelator. The cytosolic fraction showed a corresponding change (Figs. 
12G and H). An exact proportionate change in the cytosolic fraction was not evident 
compared to the membrane fraction, but overall, protein levels were much greater in the 
cytosolic fraction than the membrane fraction. Phorbol esters are very potent activators of 
PKCs (Newton, 2001) and hence phorbol 12-myristate 13-acetate (PMA) was used as a 
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positive control. Treatment with 1 μM PMA for 1 h induced a robust activation of PKCα 
in the membrane fraction (Fig. 13).  
 PKCα is activated in a Ca2+-dependent manner (Newton, 2001). The effect of 
Ca2+ ionophore, A23187, on PKCα activation was analyzed. Cells were treated with 10 
μM A23187 for 10 min or with 20 μM BAPTA-AM for 30 min prior to and during 
A23187 treatment. Activation of PKCα in the membrane fraction was observed with 
A23187 that was inhibited by BAPTA-AM (Fig. 14). This also confirmed the function of 
BAPTA-AM as an intracellular Ca2+ chelator. 
 
3.4.5 Effect of L-NAME and FeTPPS on As(III)-induced activation of PKCα 
As(III) treatment in HAECs showed no peroxynitrite formation. This was further 
confirmed by analyzing the effect of the nitric oxide synthase inhibitor, L-NAME, and 
the peroxynitrite decomposition catalyst, FeTPPS, on activation of PKCα. Peroxynitrite is 
formed by the reaction between superoxide and nitric oxide. L-NAME impedes the 
formation of nitric oxide by inhibiting nitric oxide synthase, thereby limiting 
peroxynitrite formation. Cells were treated with 10 μM As(III) for 1 h or with 50 μM L-
NAME for 1 h prior to and during As(III) treatment. Activation of PKCα was observed 
with As(III) treatment but no change was observed with L-NAME treatment (Figs. 15A 
and B). The effect of L-NAME on cell viability was assessed using the MTT assay and 
no loss of viability was observed at concentrations 10 μM-75 μM up to 24 h (data not 
shown). Treatment with 10 μM FeTPPS during 10 μM As(III) exposure for 1 h also 
showed no change in PKCα levels in the membrane fraction (Figs. 16A and B).  
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3.4.6 Effect of As(III) on the activation of PKCβ1 
The PKCβ gene consists of alternatively spliced variants, PKCβ1 and β2. Blobe et al. 
(1996) have demonstrated that the β1 and β2 isoforms display similar requirements for 
activation cofactors, phosphorylate substrates in an identical manner and are also 
inhibited to a similar extent. In addition, the kinetics of translocation to the membrane as 
well as down-regulation with PMA treatment was similar for both isoforms. Therefore, 
we initially analyzed the effect of As(III) on PKCβ1 activation by determining its 
translocation from the cytosol to the membrane. Control and 10 μM As(III) treated 
samples that were used in analyzing PKCα levels were used to detect PKCβ1 activation. 
The presence of PKCβ1 was only detected in the cytosolic fraction and no protein was 
detected in the membrane fraction at the 1-h time point (Fig. 17). Since, no activation of 
PKCβ1 was detected, the effect of As(III) on PKCβ2 was not analyzed. 
 
3.4.7 Effect of As(III) on tyrosine phosphorylation of VE-cadherin and β-catenin 
The association of VE-cadherin with β-catenin is critical for the stability of adherens 
junctions, and tyrosine phosphorylation of either one or both proteins can alter 
endothelial integrity. As(III)-induced disruption of the endothelial monolayer was evident 
starting at the 1-h time point. Therefore, the effect of As(III) exposure on tyrosine 
phosphorylation of VE-cadherin and β-catenin was analyzed at 1 h by 
immunoprecipitation followed by Western blotting. The phosphorylation of β-catenin 
was determined by probing the membrane with anti-phosphotyrosine monoclonal 
antibody following electrophoresis (Fig. 18A). The same membrane was stripped and 
total β-catenin protein content was analyzed (Fig. 18B). The tyrosine phosphorylation 
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levels were determined by normalizing with the total β-catenin protein content (Fig. 
18C). A concentration-dependent effect of As(III) exposure on tyrosine phosphorylation 
of β-catenin was observed. Treatment of cells with 1 μM As(III) showed no change in 
tyrosine phosphorylation as compared to the control (untreated), whereas an increasing 
trend in tyrosine phosphorylation was observed with 5 μM As(III), and 10 μM As(III) 
treatment resulted in a significant increase in tyrosine phosphorylation of β-catenin. The 
increase in tyrosine phosphorylation induced by 10 μM As(III) was completely inhibited 
by 250 nM Gö 6976 (Fig. 18C).  
 No tyrosine phosphorylation of VE-cadherin was observed (Fig. 18D). Even a 
basal level of tyrosine phosphorylation could not be detected. Increasing the 
concentrations of phosphatase inhibitors in the lysis buffer to confirm that VE-cadherin 
was not dephosphorylated during harvesting or immunoprecipitation did not yield any 
positive results. Analysis of the total VE-cadherin protein content established the 
presence of VE-cadherin and confirmed the adequacy of immunoprecipitation and 
Western blotting (Fig. 18E). 
 
3.4.8 Effect of As(III) on tyrosine nitration of VE-cadherin and β-catenin 
Peroxynitrite has been shown to induce nitration of β-catenin and cause disruption of the 
endothelial monolayer (Knepler et al., 2001). Although peroxynitrite generation was not 
observed with As(III) treatment, we analyzed the nitration of VE-cadherin and β-catenin. 
HAECs were treated with 10 μM As(III) for 1, 6 and 24 h, and tyrosine nitration was 
determined by immunoprecipitation followed by Western blotting. Tyrosine nitrated 
bovine serum albumin (BSA) was used as a positive control (Fig 19A). The tyrosine 
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nitration of VE-cadherin (Fig. 19B) and β-catenin (Fig. 19C) was determined by probing 
the membrane with anti-nitrotyrosine polyclonal antibody following electrophoresis. The 
same membranes were stripped and total VE-cadherin and β-catenin protein content was 
analyzed. No tyrosine nitration of VE-cadherin or β-catenin was detected at any time 
point. Analysis of the total VE-cadherin and β-catenin protein content established the 
presence of the proteins and confirmed the adequacy of immunoprecipitation and 
Western blotting. This further assured that tyrosine phosphorylation and not nitration was 
the main event following As(III) exposure. 
 
3.4.9 Effect of As(III) on VE-cadherin localization and intercellular gap formation 
Based on results from preliminary experiments, the concentration- and time-dependent 
effects of As(III) on VE-cadherin localization and intercellular gap formation were 
analyzed by immunofluorescence staining of VE-cadherin. Cells were treated with 1, 5 
and 10 μM As(III) for 1, 6, 12 and 24 h. At the 1-h time point (Fig. 20), the frequency of 
gap formation observed with 10 μM As(III) treatment (Fig. 20D) was much greater than 5 
μM As(III) (Fig. 20C) and only a few gaps were observed with 1 μM As(III) treatment 
(Fig. 20B) as compared to the untreated cells (Fig. 20A). Cells appeared to be pulling 
apart from the adjacent cells. Some areas of undamaged monolayer could be observed. 
Also, non-uniform staining of VE-cadherin was observed where the gaps appeared. To 
corroborate the fact that the observed effects were not due to cells undergoing apoptosis, 
immunofluorescence staining for cleaved caspase-3 was performed. Figs 20E and F 
demonstrate little cleaved caspase-3 staining for either untreated or 10 μM As(III) treated 
cells, respectively. The cPKC inhibitor, Gö 6976, inhibited gap formation at all 
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concentrations of As(III) treatment and uniform distribution of VE-cadherin could be 
observed at cell-cell junctions. The images of 250 nM Gö 6976 treatment alone (Fig. 
20G) and 10 μM As(III) + 250 nM Gö 6976 treatment (Fig. 20H) are shown. As with 
As(III) treatment, little and similar cleaved caspase-3 staining was observed for 250 nM 
Gö 6976 treatment alone and 10 μM As(III) + 250 nM Gö 6976 treatment (data not 
shown).  
At the 6-h time point (Fig. 21), a similar concentration-dependent effect of As(III) 
was observed but the size and frequency of gaps were greater than that observed at the 1 
h time point. Exposure to 1 μM (Fig. 21B) and 5 μM As(III) (Fig. 21C) revealed non-
uniform staining of VE-cadherin where the gaps appeared whereas treatment with 10 μM 
As(III) (Fig. 21D) resulted in loss of VE-cadherin staining at the cell-cell junctions. 
Immunofluorescence staining of cleaved caspase-3 in untreated (Fig. 21E) and 10 μM 
As(III) treated cells (Fig. 21F) revealed no differences in apoptosis. Also, Gö 6976 
inhibited gap formation at all concentrations of As(III) treatment and restored VE-
cadherin staining at the cell-cell junctions. The images of 250 nM Gö 6976 alone (Fig. 
21G) and 10 μM As(III) + 250 nM Gö 6976 treatment (Fig. 21H) are shown. As with 
As(III), little and similar cleaved caspase-3 staining was observed for 250 nM Gö 6976 
treatment alone and 10 μM As(III) + 250 nM Gö 6976 treatment (data not shown). 
At the 12-h (Fig. 22A-H) and 24-h (Fig. 23A-H) time points, the concentration-
dependent effects of As(III) treatment were similar to those seen at earlier time points. 
However, the frequency and size of gaps observed were maximal at the 6-h time point.  
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3.4.10 Effect of As(III) treatment on VE-cadherin protein content 
The immunofluorescence results in Figs. 20-23 showed that VE-cadherin distribution was 
altered by As(III) exposure. Therefore, the effects of 1, 5, and 10 μM As(III) treatments 
on the protein levels of VE-cadherin at the 24-h time point were determined. Western 
blotting analysis revealed a concentration-dependent effect of As(III) on VE-cadherin 
protein levels in the HAECs (Figs. 24A and B). Approximately 8, 15 and 30% reductions 
in VE-cadherin protein were observed with 1, 5 and 10 μM As(III) treatment, 
respectively, compared to the control (untreated) HAECs (Fig. 24B).  
 
3.4.11 Effect of As(III) exposure on β-catenin localization 
The cytoplasmic domain of VE-cadherin is linked with β-catenin, so it was of interest to 
determine whether As(III) affects β-catenin distribution. Exposure to As(III) for 6 h 
revealed the most damaging effects on the endothelial monolayer. Hence, the effect of 
As(III) treatment on β-catenin localization in HAECs was analyzed by 
immunofluorescence staining at the 6-h time point (Fig. 25). As previously observed with 
VE-cadherin localization, β-catenin staining showed a corresponding concentration-
dependent effect with As(III) treatment. The frequency of gap formation with 10 μM 
As(III) (Fig. 25D) was greater than 5 μM As(III) (Fig. 25C) and only a few gaps were 
observed with 1 μM As(III) treatment (Fig. 25B). Non-uniform distribution or loss of β-
catenin staining was evident wherever gaps could be observed. Also, 250 nM Gö 6976 
treatment inhibited the gap formation induced by 10 μM As(III) (Fig. 25E) and restored 
the β-catenin staining at cell-cell junctions. 
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3.4.12 Effect of As(III) exposure on the formation of stress fibers 
The cadherin/β-catenin complex is associated with the actin cytoskeleton, and this 
association is very important for maintaining junctional stability and structural integrity 
of the endothelial cell monolayer. As previously mentioned, reorganization of actin 
microfilaments into stress fibers can adversely affect monolayer integrity. Hence, the 
effects of 1, 5 and 10 μM As(III) on reorganization of actin microfilaments were analyzed 
at 1, 6, 12 and 24 h by immunofluorescence staining using fluorophore-conjugated 
phalloidin. A concentration- and time-dependent effect of As(III) treatment was 
observed. At the 1-h time point (Fig. 26), As(III) induced a concentration-dependent 
increase in stress fibers with the maximum stress fibers being observed with 10 μM 
As(III) treatment (Fig. 26D). Treatment with Gö 6976 abolished the stress fiber formation 
at all concentrations of As(III) treatment. The images of 250 nM Gö 6976 treatment alone 
(Fig. 26E) and 10 μM As(III) + 250 nM Gö 6976 treatment (Fig. 26F) are shown. 
 At the 6-h time point (Fig. 27), the frequency and density of stress fibers induced 
by As(III) was much higher than that observed at the 1-h time point. Also, a 
concentration-dependent increase in stress fibers was observed with the maximum stress 
fibers being induced with 10 μM As(III) treatment (Fig. 27D). Treatment with Gö 6976 
reduced the stress fibers at all concentrations of As(III) treatment. The images of 250 nM 
Gö 6976 treatment alone (Fig. 27E) and 10 μM As(III) + 250 nM Gö 6976 treatment 
(Fig. 27F) are shown.  
At the 12-h (Fig. 28A-F) and 24-h (Fig. 29A-F) time points, similar 
concentration-dependent effects of As(III) treatment were observed. Stress fiber 
formation, like the intercellular gap formation, was maximal at the 6-h time point. 
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3.4.13 Effect of As(III) on endothelial permeability 
Exposure to As(III) caused detrimental effects on the endothelial monolayer and induced 
reorganization of actin microfilaments into stress fibers. Therefore, we hypothesized that 
As(III) would also increase endothelial permeability. The effect of 1, 5 and 10 μM As(III) 
treatment on endothelial permeability was analyzed at the 6-h time point (Fig. 30). 
Confluent monolayers of HAECs grown on Transwell inserts were treated with various 
As(III) concentrations, and the permeability of the monolayer for FITC-dextran was 
determined by measuring the fluorescence intensity of the medium in the plate well. A 
5% increase in permeability was observed with 1 and 5 μM As(III) treatment, whereas 10 
μM As(III) induced approximately a 19% increase. Treatment with 250 nM Gö 6976 
inhibited the increase in permeability induced by 10 μM As(III). 
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3.5 Figures 
Table. 2. Cell viability after As(III) treatment 
Time 12 h 24 h 48 h 
IC50  103 μM 40 μM 23 μM 
Threshold 50 μM 10 μM 5 μM 
 
Table. 2. Cell viability after As(III) treatment. HAECs were treated with As(III) up to 
500 μM for 12, 24 and 48 h. Cell viability was determined using the MTT colorimetric 
assay.  
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Fig. 10. Effect of As(III) on peroxynitrite formation 
A.  
 
B.  
 
C. 
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Fig. 10. Effect of As(III) on peroxynitrite formation. (A) Confluent HAECs were treated 
with 1, 5 and 10 μM As(III) for 24 h and the formation of 3-nitrotyrosine was analyzed 
by immunofluorescence. The control (100%) is indicated by dotted line and the graph is 
representative of 2 independent experiments performed. (B) Confluent BAECs were 
treated with 10 μM As(III) for 24 h and the formation of 3-nitrotyrosine was analyzed by 
immunofluorescence quantification. Error bars represent mean ± SEM for n=3 and * 
indicates significantly different from control with p<0.05. (C) Confluent HAECs were 
treated with 1, 5 and 10 μM As(III) or 10 μM FeTPPS in the presence of 10 μM As(III) 
for 1 h and the formation of peroxynitrite was analyzed based on the oxidation of 
hydroethidine to ethidium. Error bars represent mean ± SEM for n=4-5. 
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Fig. 11. Dose response of HAECs to cPKC inhibitor Gö 6976 
 
Fig. 11. Dose response of HAECs to cPKC inhibitor Gö 6976. Confluent HAEC 
monolayers were either untreated (A) or treated with 10 μM As(III) (B) for 1 h and the 
intercellular gaps (indicated with arrows) were visualized by immunofluorescence 
staining of VE-cadherin (green). The nuclei were stained with Hoechst (blue). Pretreating 
the cells with increasing concentration of Gö 6976 for 1 h prior to and during 10 μM 
As(III) treatment inhibited the gap formation in a concentration-dependent manner: 10 
μM As(III) + 10 nM Gö 6976 (C), 10 μM As(III) + 50 nM Gö 6976 (D), 10 μM As(III) + 
100 nM Gö 6976 (E), 10 μM As(III) + 250 nM Gö 6976 (F), 10 μM As(III) + 500 nM Gö 
6976 (G) and 10 μM As(III) + 1 μM Gö 6976 (H). Magnification=60X. The images are 
representative of 3 independent experiments performed. 
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Fig. 12. Effect of As(III) on the activation of PKCα 
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Fig. 12. Effect of As(III) on the activation of PKCα. Confluent HAECs were treated with 
1, 5, and 10 μM As(III) for 1 h or pretreated with 250 nM Gö 6976 and 20 μM BAPTA-
AM for 1 h and 30 min, respectively, prior to and during 10 μM As(III) treatment. The 
lysates were subjected to ultracentrifugation to separate the membrane and cytosolic 
fractions and the PKCα levels in both fractions were determined by Western blotting. The 
PKCα content in the membrane fraction is shown in (A and E) upper panel and the lower 
panel represents the Na+/K+ ATPase loading control for the membrane fraction. The 
percent change in PKCα content in the membrane fraction relative to the control 
(untreated) is represented in (B and F). The PKCα content in the cytosolic fraction is 
shown in (C and G) upper panel and the lower panel represents the GAPDH loading 
control for the cytosolic fraction. The percent change in PKCα content in the cytosolic 
fraction relative to the control is represented in (D and H). The images in (A, C, E and G) 
are representative of 3-6 independent experiments performed. The control (100%) is 
indicated by the dotted line in (B, D, F and H). Error bars represent mean ± SEM for n=3-
6. * and # indicates significantly different from control and 10 μM As(III), respectively, 
with p<0.05.  
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Fig. 13. Effect of As(III) and PMA on the activation of PKCα 
 
 
 
Fig. 13. Effect of As(III) and PMA on the activation of PKCα. Confluent HAECs were 
treated with 10 μM As(III) or the positive control 1 μM PMA for 1 h. The lysates were 
subjected to ultracentrifugation to separate the membrane and cytosolic fractions and the 
PKCα levels were determined by Western blotting. The PKCα content in the membrane 
fraction is shown. The image is from one experiment performed. 
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Fig. 14. Effect of A23187 on the activation of PKCα 
 
 
Fig. 14. Effect of A23187 on activation of PKCα. Confluent HAECs were treated with 10 
μM A23187 for 10 min or pretreated with 20 μM BAPTA-AM for 30 min prior to and 
during 10 μM A23187 treatment. The lysates were subjected to ultracentrifugation to 
separate the membrane and cytosolic fractions and the PKCα levels were determined by 
Western blotting. The PKCα content in the membrane fraction is shown in the upper 
panel and the lower panel represents the Na+/K+ ATPase loading control for the 
membrane fraction. The image is from one experiment performed. 
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Fig. 15. Effect of L-NAME on As(III)-induced activation of PKCα 
A.  
 
B. 
 
Fig. 15. Effect of L-NAME on As(III)-induced activation of PKCα. Confluent HAECs 
were treated with 10 μM As(III) for 1 h or pretreated with 50 μM L-NAME for 1 h prior 
to and during As(III) treatment. The lysates were subjected to ultracentrifugation to 
separate the membrane and cytosolic fractions and the PKCα levels in both fractions were 
determined by Western blotting. The PKCα content in the membrane fraction is shown in 
(A) upper panel and the lower panel represents the Na+/K+ ATPase loading control for 
the membrane fraction. The percent change in PKCα content in the membrane fraction 
relative to the control (untreated) is represented in (B). The control (100%) is indicated 
by the dotted line in (B). The image (A) is representative of 5-6 independent experiments 
performed. Error bars represent mean ± SEM for n=5-6. * indicates significantly different 
from control with p<0.001. 
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Fig. 16. Effect of FeTPPS on As(III)-induced activation of PKCα 
A. 
 
B.  
 
Fig. 16. Effect of FeTPPS on As(III)-induced activation of PKCα. Confluent HAECs 
were treated with 10 μM As(III) or 10 μM FeTPPS in the presence of 10 μM As(III) for 1 
h. The lysates were subjected to ultracentrifugation to separate the membrane and 
cytosolic fractions and the PKCα levels were determined by Western blotting. The PKCα 
content in the membrane fraction is shown in (A) upper panel and the lower panel 
represents the Na+/K+ ATPase loading control for the membrane fraction. The percent 
change in PKCα content in the membrane fraction relative to the control (untreated) is 
represented in (B). The control (100%) is indicated by the dotted line in (B). The image 
(A) is representative of 2 independent experiments performed. 
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Fig. 17. Effect of As(III) on the activation of PKCβ1 
 
 
Fig. 17. Effect of As(III) on the activation of PKCβ1. Confluent HAECs were treated with 
10 μM As(III) for 1 h. The lysates were subjected to ultracentrifugation to separate the 
membrane and cytosolic fractions and the PKCβ1 levels in both fractions were 
determined by Western blotting. The image is representative of 2 independent 
experiments performed. 
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Fig. 18. Effect of As(III) on tyrosine phosphorylation of β-catenin and VE-cadherin 
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Fig. 18. Effect of As(III) on tyrosine phosphorylation of β-catenin and VE-cadherin. 
Confluent HAECs were treated with 1, 5, and 10 μM As(III) for 1 h or pretreated with 
250 nM Gö 6976 for 1 h prior to and during 10 μM As(III) treatment. The β-catenin was 
immunoprecipitated, and Western blotting technique was used to analyze the 
phosphorylation of tyrosine residues (A). The membrane was stripped and reprobed to 
determine the total β-catenin protein content (B). The images A and B are representative 
of 4-6 independent experiments performed. The percent change in tyrosine 
phosphorylation with the various treatments relative to the control (untreated) is 
represented in (C). The control (100%) is indicated by the dotted line. Error bars 
represent mean ± SEM for n=4-6. * and # indicates significantly different from control 
and 10 μM As(III), respectively, with p<0.05. Similarly, the VE-cadherin protein was 
immunoprecipitated, and Western blotting technique was used to analyze the 
phosphorylation of tyrosine residues (D). The membrane was stripped and reprobed to 
determine the total VE-cadherin protein content (E). The images D and E are 
representative of 2 independent experiments performed. 
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Fig. 19. Effect of As(III) on tyrosine nitration of VE-cadherin and β-catenin 
 
Fig. 19. Effect of As(III) on tyrosine nitration of VE-cadherin and β-catenin. Confluent 
HAECs were treated with 10 μM As(III) for 1, 6 and 24 h. The VE-cadherin and β-
catenin proteins were immunoprecipitated, and Western blotting technique was used to 
analyze the nitration of tyrosine residues (B and C upper panel). The membranes were 
stripped and reprobed to determine the total VE-cadherin and β-catenin protein content 
(B and C lower panel). The images in A, B and C are from one experiment performed. 
Nitrated BSA was used as a positive control (A). 
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Fig. 20. Effect of As(III) on VE-cadherin localization and intercellular gap 
formation at the 1-h time point 
 
 
Fig. 20. Effect of As(III) on VE-cadherin localization and intercellular gap formation at 
the 1-h time point. Confluent HAEC monolayers were either untreated (A) or treated with 
1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 1 h and the intercellular 
gaps (indicated with arrows) induced with As(III) treatment were visualized by 
immunofluorescence staining of VE-cadherin (green). The nuclei were stained with 
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III) 
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h 
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps 
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial 
monolayer. Magnification=60X. The images are representative of 4 independent 
experiments performed. 
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Fig. 21. Effect of As(III) on VE-cadherin localization and intercellular gap 
formation at the 6-h time point.  
 
 
Fig. 21. Effect of As(III) on VE-cadherin localization and intercellular gap formation at 
the 6-h time point. Confluent HAEC monolayers were either untreated (A) or treated with 
1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 6 h and the intercellular 
gaps (indicated with arrows) induced with As(III) treatment were visualized by 
immunofluorescence staining of VE-cadherin (green). The nuclei were stained with 
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III) 
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h 
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps 
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial 
monolayer. Magnification=60X. The images are representative of 4 independent 
experiments performed. 
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Fig. 22. Effect of As(III) on VE-cadherin localization and intercellular gap 
formation at the 12-h time point. 
 
 
Fig. 22. Effect of As(III) on VE-cadherin localization and intercellular gap formation at 
the 12-h time point. Confluent HAEC monolayers were either untreated (A) or treated 
with 1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 12 h and the 
intercellular gaps (indicated with arrows) induced with As(III) treatment were visualized 
by immunofluorescence staining of VE-cadherin (green). The nuclei were stained with 
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III) 
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h 
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps 
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial 
monolayer. Magnification=60X. The images are representative of 4 independent 
experiments performed. 
 126
 
Fig. 23. Effect of As(III) on VE-cadherin localization and intercellular gap 
formation at the 24-h time point 
 
 
Fig. 23. Effect of As(III) on VE-cadherin localization and intercellular gap formation at 
the 24-h time point. Confluent HAEC monolayers were either untreated (A) or treated 
with 1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) (D) for 24 h and the 
intercellular gaps (indicated with arrows) induced with As(III) treatment were visualized 
by immunofluorescence staining of VE-cadherin (green). The nuclei were stained with 
Hoechst (blue). Cleaved caspase-3 staining (green) for untreated (E) and 10 μM As(III) 
(F) treated cells is indicated by arrowheads. Pretreatment with 250 nM Gö 6976 for 1 h 
prior to and during 10 μM As(III) treatment (H) inhibited the As(III) induced gaps 
whereas 250 nM Gö 6976 treatment alone (G) did not have any effect on the endothelial 
monolayer. Magnification=60X. The images are representative of 4 independent 
experiments performed. 
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Fig. 24. Effect of As(III) treatment on VE-cadherin protein content 
A. 
 
 
B. 
 
Fig. 24. Effect of As(III) treatment on VE-cadherin protein content. Confluent HAECs 
were treated with 1, 5 and 10 μM As(III) for 24 h and VE-cadherin protein content was 
analyzed by Western blotting technique. The VE-cadherin protein content is shown in the 
(A) upper panel and the lower panel represents the β-actin loading control. The images in 
(A) are representative of 7 experiments performed. The percent change in VE-cadherin 
protein relative to the control (untreated) is represented in (B). The control (100%) is 
indicated by the dotted line in (B). Error bars represent mean ± SEM for n=7. * indicates 
significantly different from control with p<0.05.  
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Fig. 25. Effect of As(III) exposure on β-catenin localization 
 
 
Fig. 25. Effect of As(III) exposure on β-catenin localization. Confluent HAECs were 
either untreated (A) or treated with 1 μM As(III) (B), 5 μM As(III) (C) and 10 μM As(III) 
(D) for 6 h and β-catenin localization was visualized by immunofluorescence staining 
(green). Non-uniform staining or loss of β-catenin was observed wherever gaps occurred 
(indicated by arrows). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 
μM As(III) treatment (E) restored the β-catenin localization at cell-cell junctions. The 
nuclei were stained with Hoechst (blue). Magnification=60X. The images are 
representative of 3 independent experiments performed. 
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Fig. 26. Effect of As(III) exposure on formation of stress fibers at the 1-h time point 
 
Fig. 26. Effect of As(III) exposure on formation of stress fibers at the 1-h time point. 
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B), 
5 μM (C) and 10 μM (D) for 1 h and the stress fibers induced with As(III) treatment were 
visualized by immunofluorescence staining with Alexa Fluor 568-conjugated phalloidin 
(red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM As(III) 
treatment (F) inhibited the As(III) induced stress fibers whereas 250 nM Gö 6976 
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X. 
The images are representative of 4 independent experiments performed. 
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Fig. 27. Effect of As(III) exposure on formation of stress fibers at the 6-h time point 
 
Fig. 27. Effect of As(III) exposure on formation of stress fibers at the 6-h time point. 
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B), 
5 μM (C) and 10 μM (D) for 6 h and the stress fibers induced with As(III) treatment were 
visualized by immunofluorescence staining with Alexa Fluor 568-conjugated phalloidin 
(red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM As(III) 
treatment (F) reduced the As(III) induced stress fibers whereas 250 nM Gö 6976 
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X. 
The images are representative of 4 independent experiments performed. 
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Fig. 28. Effect of As(III) exposure on formation of stress fibers at the 12-h time 
point. 
 
 
Fig. 28. Effect of As(III) exposure on formation of stress fibers at the 12-h time point. 
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B), 
5 μM (C) and 10 μM (D) for 12 h and the stress fibers induced with As(III) treatment 
were visualized by immunofluorescence staining with Alexa Fluor 568-conjugated 
phalloidin (red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM 
As(III) treatment (F) inhibited the As(III) induced stress fibers whereas 250 nM Gö 6976 
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X. 
The images are representative of 4 independent experiments performed. 
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Fig. 29. Effect of As(III) exposure on formation of stress fibers at the 24-h time point 
 
Fig. 29. Effect of As(III) exposure on formation of stress fibers at the 24-h time point. 
Confluent HAEC monolayers were either untreated (A) or treated with As(III); 1 μM (B), 
5 μM (C) and 10 μM (D) for 24 h and the stress fibers induced with As(III) treatment 
were visualized by immunofluorescence staining with Alexa Fluor 568-conjugated 
phalloidin (red). Pretreatment with 250 nM Gö 6976 for 1 h prior to and during 10 μM 
As(III) treatment (F) inhibited the As(III) induced stress fibers whereas 250 nM Gö 6976 
treatment alone (E) did not have an effect on stress fiber formation. Magnification=60X. 
The images are representative of 4 independent experiments performed. 
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Fig. 30. Effect of As(III) on endothelial permeability 
 
 
Fig. 30. Effect of As(III) on endothelial permeability. Confluent HAECs were treated 
with 1, 5, and 10 μM As(III) for 6 h or pretreated with 250 nM Gö 6976 for 1 h prior to 
and during 10 μM As(III) treatment. Monolayer permeability was measured using FITC-
dextran. The control (100%) is indicated by the dotted line. Error bars represent mean ± 
SEM for n=4-5. 
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3.6 Discussion 
The results from this study show that PKCα is a key mediator in the proposed 
mechanism for As(III)-induced atherosclerosis. The data shows that PKCα plays a crucial 
role in localization of the adherens junction proteins, VE-cadherin and β-catenin, and in 
regulating endothelial gap formation, stress fiber formation and vascular permeability. 
As(III) treatment induced intercellular gaps thereby disrupting the endothelial monolayer 
as evidenced by loss or non-uniform staining of VE-cadherin and β-catenin where the 
gaps appeared. Reduced VE-cadherin protein content was also detected; a finding that 
may in part be responsible for the observed intercellular gaps. An increased plasma 
concentration of VE-cadherin has been associated with coronary atherosclerosis (Soeki et 
al., 2004), and in vitro studies have shown that hydrogen peroxide induces internalization 
of VE-cadherin and gap formation (Kevil et al., 1998). Hence, the decreased VE-cadherin 
may be due to internalization and degradation or release into the cell culture medium.  
β-catenin was found to be phosphorylated with 5 and 10 μM As(III) treatments, 
but no tyrosine phosphorylation of VE-cadherin was detected. There are several non-
receptor tyrosine kinases such as Fyn, Fer, cMet, Abl and Src that have been shown to 
associate with and modulate the phosphorylation state of β-catenin and its association 
with cadherin (Lilien and Balsamo, 2005) during various developmental and 
physiological processes. In particular, phosphorylation of β-catenin at tyrosine 654 by Src 
has been shown to cause a fivefold reduction in its affinity for E-cadherin (Roura et al., 
1999), which belongs to the same class of type I classical cadherins as VE-cadherin 
(Ivanov et al., 2001). The phosphorylation and dephosphorylation state of adherens 
junction proteins plays a critical role in the formation and/or maintenance of stable cell-
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cell adhesions (Lilien and Balsamo, 2005, Schnittler, 1998). Therefore, tyrosine 
phosphorylation of β-catenin could potentially reduce its affinity for association with VE-
cadherin and cause dissociation or loosening of the adherens junctions. As(III) has been 
shown to stimulate Src kinase activity in intact endothelial cells, but not recombinant Src 
activity (Barchowsky et al., 1999b). This suggests that As(III) does not affect Src activity 
directly, but one or more intermediates likely exist between As(III) and Src activation, 
one of which potentially could be PKC. Consistent with this, Chang et al. (2001) have 
demonstrated that association of activated PKC with the anchoring protein, receptor for 
activated C kinase, promotes its binding to Src tyrosine kinase. Therefore, a cooperative 
interaction between PKC and Src is feasible. This may explain the tyrosine 
phosphorylation of β-catenin as a consequence of PKC activation, which is a 
serine/threonine kinase.  
Arsenic has been shown to increase Ca2+-dependent PKC activity in Chinese 
hamster ovary cells at high doses after 4-h treatment (Liu and Huang, 1997). Similarly, 
transient activation of PKCα was observed with 20 μM arsenic treatment in a mouse 
epidermal cell line (Chen et al., 2000). Our results showed that 5 and 10 μM As(III) 
treatment induced significant activation of PKCα at the 1-h time point in a Ca2+-
dependent manner. The downstream effects of As(III)-induced PKCα activation were 
confirmed by using the cPKC inhibitor, Gö 6976. Inhibition of PKCα prevented gap 
formation and restored VE-cadherin and β-catenin at the cell-cell junctions. Tyrosine 
phosphorylation of β-catenin induced by As(III) was also reduced to basal levels. The 
effects of activation of PKCα and β on endothelial integrity in different 
pathophysiological circumstances have been well documented (Yuan, 2003). Activation 
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of PKCα by thrombin has been shown to modulate endothelial integrity by induction of 
stress fibers and increased endothelial permeability (Sandoval et al., 2001). Also, tyrosine 
phosphorylation of β-catenin has been observed that is cPKC-dependent (Cohen et al., 
1999). Activation of PKCβ1 was not detected with As(III) treatment. The PKCβ1 and β2 
isoforms have been shown to follow similar activation/membrane translocation kinetics 
in several cell lines using similar activators (Blobe et al., 1996, Goodnight et al., 1995, 
Wang et al., 2004). Therefore, it appears that PKCα and not PKCβ plays a significant role 
in As(III)-induced endothelial disruption.  
Formation of stress fibers induced by As(III) was also abolished or reduced with 
Gö 6976 treatment. Studies have demonstrated the relation between PKCα activation, 
stress fiber formation and cell contraction. It has been found that PKCα induces the 
activation of myosin by serine/threonine phosphorylation of myosin light chain, which 
results in actin-myosin interaction and subsequent stress fiber formation and cell 
contraction (Tiruppathi et al., 2003). Therefore, PKC inhibition plausibly inhibited the 
contractile force exerted by the stress fibers. Confluent endothelial cells consist of a band 
of actin filaments concentrated along the cell borders known as a dense peripheral band 
(DPB) that is also present in vivo (Gabbiani et al., 1983, Schnittler, 1998). The cadherin-
catenin complex associates with the actin filaments of DPB, which is important for 
junctional stability. Our results showed that actin filaments were present in untreated 
cells along the cell borders and were mostly absent in central regions of the cell. 
Treatment with As(III) resulted in loss of DPB and an increase in stress fibers traversing 
the cells. The effect of As(III) was observed to be concentration- and time-dependent 
with the maximum stress fibers being formed with 10 μM As(III) at the 6-h time point. 
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Actin reorganization associated with disruption of the endothelial barrier is characterized 
by increased stress fiber density and reduction or loss of DPB (Lum and Roebuck, 2001). 
Stress fibers have the molecular machinery to generate contractile force and have been 
associated with gap formation and increased endothelial permeability (Pellegrino et al., 
2004, Yuan, 2003).  
 Vascular permeability changes are associated with loss of endothelial integrity. 
Chen et al. (2004) and Tsai et al. (2005) showed that As(III) alters endothelial 
permeability in rodents. Using FITC-dextran, we found a 5% increase in endothelial 
permeability with 1 and 5 μM As(III) and approximately a 19% increase with 10 μM 
As(III) treatment that was inhibited by Gö 6976 treatment. These changes were not as 
great as expected based on the gap formation observed and actin stress fiber formation. 
However, Chen et al. (2004) and Tsai et al. (2005) have clearly demonstrated that even a 
small increase in permeability could be pathologically important. Taken together, these 
results suggest that As(III) induces tyrosine phosphorylation of β-catenin, which 
modulates adherens junction assembly resulting in non-uniform distribution or loss of 
VE-cadherin as well as β-catenin at the cell-cell junctions and promotes the formation of 
stress fibers which culminates in intercellular gap formation and increased permeability. 
 As(III) has been shown to modulate several signaling pathways by generation of 
oxidative and nitrosative stress in different cell systems such as BAECs and porcine 
aortic endothelial cells (Barchowsky et al., 1996, Barchowsky et al., 1999a, Bunderson et 
al., 2002). In particular, peroxynitrite and its donor, SIN-1, have been shown to induce 
nitration of PKCα, actin as well as β-catenin and alter their function (Knepler et al., 2001, 
Chakraborti et al., 2005, Knapp et al., 2001). We hypothesized, therefore, that As(III)-
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induced peroxynitrite may play a role in endothelial barrier modulation. However, no 
peroxynitrite generation was observed with As(III) treatment in HAECs, although an 
increase was observed in BAECs. This was confirmed by the absence of nitration of VE-
cadherin and β-catenin as well as an inability by a nitric oxide synthase inhibitor and a 
peroxynitrite decomposition catalyst, L-NAME and FeTPPS, to inhibit PKCα activation. 
The generation of reactive species with As(III) has been observed to be species specific. 
For example, no nitric oxide formation was observed with As(III) (<5 μM) in porcine 
aortic endothelial cells (Barchowsky et al., 1999a) whereas Kao et al. (2003), 
demonstrated that As(III) (<5 μM) induces the production of nitric oxide in HUVECs. 
The observed differences could also be attributed to different experimental conditions. 
The differential effects of As(III) in the production of reactive species have been 
reviewed in detail by Gurr et al. (2003) and Kumagai and Pi, (2004).  
While the results presented here show PKCα dependency for the effects of As(III) 
on endothelial cell-cell adhesion, monolayer integrity and vascular permeability, they do 
not suggest that As(III) effects on endothelium are restricted to the PKCα pathway. Other 
signal transduction pathways intersect with PKCα signaling. The PKC enzymes are 
serine/threonine kinases, and it has been suggested that crosstalk exists between the 
tyrosine and serine/threonine kinase signaling cascades (Bauman and Scott, 2002, Chang 
et al., 2001). Involvement of tyrosine kinases introduces the possibility that vascular 
endothelial growth factor (VEGF), a key modulator of adherens junction stability that 
signals through a tyrosine kinase pathway, may be involved. VEGF has been implicated 
in arsenic-related toxicity through activation of PKCδ in smooth muscle cells (Soucy et 
al., 2004). In addition, the VEGF receptor tyrosine kinases have been shown to signal 
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with PKCα activation and downstream AKT signaling (Gliki et al., 2002). Moreover, 
VEGF signals through a Ras-MEK-ERK pathway independent of PKCα suggesting that 
not all As(III)-related effects may be PKCα dependent. Stress kinases such as p38 and c-
Jun amino-terminal kinase (JNK) could also potentially be involved in the observed 
effects of As(III). Barchowsky et al. (1999b) showed that high levels of As(III) can 
induce cellular stress and activate stress kinases including p38. On the other hand, lower 
concentrations have been shown to induce DNA synthesis and reactive oxygen species 
(Barchowsky et al., 1996) without activating stress kinases (Barchowsky et al., 1999b). 
The role of these alternative pathways in endothelial arsenic toxicity is the subject for 
future investigations. 
In summary, we have determined a potential mechanism for arsenic-induced 
atherosclerosis. This study demonstrates that As(III)-induced activation of PKCα leads to 
tyrosine phosphorylation of β-catenin and formation of stress fibers. Tyrosine 
phosphorylation of β-catenin may cause weakening of the adherens junctions, and this 
effect, in association with the contractile force generated by stress fibers, results in gap 
formation and increased endothelial permeability. Proteins at the adherens junctions are 
largely responsible for maintaining the barrier and normally allow passage of selected 
molecules. Injury to the endothelium can promote accumulation of oxLDLs and 
monocytes/macrophages in the intima of blood vessels (Lusis, 2000), ultimately leading 
to formation of foam cells. The intercellular gaps and increased permeability caused by 
arsenic could potentially accelerate/enhance influx of oxLDLs and 
monocytes/macrophages across the endothelium and contribute significantly to the 
progression of atherosclerosis. 
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Chapter 4 
Conclusions 
 
4.1 Conclusions 
Arsenic contamination of ground water is a global problem and millions of people 
worldwide are exposed to arsenic through drinking water. Arsenic exposure has been 
associated with the development of cardiovascular diseases such as carotid 
atherosclerosis (Wang et al., 2002), ischemic heart disease (Tseng et al., 2003) and 
hypertension (Rahman et al., 1999). Atherosclerosis is the fundamental cause of major 
cardiovascular diseases including ischemic heart disease, myocardial infarction and 
stroke. Arsenic levels exceeding 20 ppb in drinking water have been associated with 
increased mortality from various cardiovascular diseases (Engel and Smith, 1994). In 
addition to the United States, other countries including Taiwan, Bangladesh, India, China, 
Vietnam and Argentina have high levels of arsenic in ground water ranging from 50-
14,000 ppb (Wang and Wai, 2004). 
 Our laboratory has focused on elucidating the mechanisms of arsenic-induced 
atherosclerosis. In this study, the role of arsenic in atherogenesis was determined by (1) 
characterizing the time- and concentration-dependent effects of sodium arsenite [As(III)] 
on the initiation and progression of atherosclerosis in ApoE-/- /LDLr-/- atherosclerotic 
mouse model, (2) determining the effects of As(III)-induced peroxynitrite on the 
activation of calcium dependent cPKC isotypes, α and β, in human aortic endothelial cells 
and (3) determining whether activation of cPKC isotypes, α and β, by As(III) are 
involved in endothelial barrier disruption. 
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 The time- and concentration-dependent effects of environmentally relevant 
concentrations of arsenic in the development of atherosclerosis were investigated using 
the ApoE-/- /LDLr-/- mouse model that is a well-established animal model of human 
atherosclerosis (Ishibashi et al., 1994, Jawein et al., 2004). Atherosclerotic plaque 
development was determined by measuring the percent occlusion of the innominate 
artery, which is a small vessel that connects the aortic arch to the right subclavian and 
right carotid arteries. Development of atherosclerotic lesions in this artery has been 
shown to progress at a highly consistent rate and closely resemble that of the human 
condition (Rosenfeld et al., 2000).  
The temporal effects of arsenic were determined by exposing the mice to 10 ppm 
As(III) in drinking water for 5 or 10 weeks. Histology revealed that mice treated with 
As(III) showed an increasing trend in atherosclerotic plaque formation within the 
innominate arteries compared to the controls at both 5 and 10 weeks. Analysis of IL-6 
levels in the serum obtained from mice treated with As(III) for 10 weeks showed an 
increasing trend compared to the control mice. These results suggest that As(III) 
contributes to atherogenesis at an early stage of the disease.  
The concentration-dependent effects of arsenic were analyzed by exposing the 
ApoE-/- /LDLr-/- mice to 1, 5 and 10 ppm As(III) in drinking water for 20 weeks. A 
significant increase in occlusion of the innominate arteries was observed with 1 and 5 
ppm As(III). Our laboratory has previously shown that exposure to 10 ppm As(III) for 18 
weeks significantly increases atherosclerotic plaque formation in ApoE-/- /LDLr-/- mice 
(Bunderson et al., 2004). However, in this study an increasing trend in occlusion was 
observed with 10 ppm As(III), and serum IL-6 levels were significantly elevated in this 
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group. These results demonstrate the significance of low levels of arsenic in the onset and 
progression of atherosclerosis in this animal model. Surprisingly, sVCAM-1 levels were 
lower at both the 10 and 20 week time points in 10 ppm As(III) treated mice compared to 
the control mice. However, this does not suggest that there is reduced expression of 
endothelial VCAM-1. 
 The endothelium is the most important barrier between the blood and vessel wall 
and it that allows passage of only selected molecules. Damage to the endothelium can 
result in increased permeability and promote the accumulation of oxidized LDLs and 
monocytes into the blood vessel intima. Chen et al. (2004) and Tsai et al. (2005) have 
documented that As(III) increases endothelial permeability in rodents. Also, As(III) 
exacerbates the development of atherosclerosis (Bunderson et al., 2004, Simeonova et al., 
2003). Therefore, a rational approach was to determine whether As(III) affects the 
integrity of the endothelial monolayer. 
 We determined the role of PKCα and β in As(III)-mediated disruption of 
endothelial monolayer integrity. The translocation of PKC from cytosol to the membrane 
is an important step in its activation process (Newton, 2001). Therefore, HAECs were 
exposed to 1, 5 and 10 μM As(III), and cPKC activation was analyzed at the 1-h time 
point by determining the protein content in the membrane and cytosolic fractions by 
Western blotting technique. Treatment with 5 and 10 μM As(III) induced a significant 
increase in PKCα activation as determined by quantifying the protein content in the 
membrane fraction. No change was observed with 1 μM As(III) treatment. In the 
cytosolic fraction, a decrease in the PKCα content was observed with increasing As(III) 
concentration indicative of PKCα translocation from the cytosol to the membrane. 
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Treatment of the cells with the cPKC inhibitor, 250 nM Gö 6976, for 1 h or with the 
intracellular Ca2+ chelator, 20 μM BAPTA-AM, for 30 min, prior to and during 10 μM 
As(III) treatment inhibited the PKCα activation. The phorbol ester, PMA, and Ca2+ 
ionophore, A23187, were used as positive controls. PKCβ1 was only detected in the 
cytosolic fraction and no protein was detected in the membrane fraction at the 1-h time 
point. Since, no activation of PKCβ1 was detected, the effect of As(III) on PKCβ2 was not 
analyzed. 
 As(III) treatment failed to induce generation of peroxynitrite in HAECs as 
analyzed by immunofluorescence staining for 3-nitrotyrosine as well as with the 
hydroethidine assay that measures the conversion of hydroethidine to its oxidized 
fluorescent product ethidium. Also, pretreatment of HAECs with the peroxynitrite 
decomposition catalyst, FeTPPS, or the nitric oxide synthase inhibitor, L-NAME, did not 
inhibit/affect the activation of PKCα. However, a significant increase in 3-nitrotyrosine 
was observed in BAECs treated with 10 μM As(III).  
 The integrity of the vascular endothelium is largely maintained by proteins of the 
adherens junctions; VE-cadherin and β-catenin. The association of VE-cadherin with β-
catenin is critical for the stability of adherens junctions, and tyrosine phosphorylation of 
either one or both the proteins can alter endothelial integrity. The effect of As(III) 
exposure on tyrosine phosphorylation of VE-cadherin and β-catenin was analyzed at 1 h 
in HAECs by immunoprecipitation followed by Western blotting. Treatment of cells with 
1 μM As(III) showed no change in tyrosine phosphorylation as compared to the control 
(untreated), whereas an increasing trend in tyrosine phosphorylation was observed with 5 
μM As(III), and 10 μM As(III) treatment resulted in a significant increase in tyrosine 
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phosphorylation of β-catenin. The increase in tyrosine phosphorylation induced by 10 μM 
As(III) was completely inhibited by 250 nM Gö 6976. No tyrosine phosphorylation of 
VE-cadherin was detected. Also, no tyrosine nitration of VE-cadherin or β-catenin was 
detected, which further confirmed the absence of peroxynitrite generation with As(III) 
treatment. 
 The effect of As(III) on cell-cell adhesion was analyzed with immunofluorescence 
staining for VE-cadherin. HAECs were treated with 1, 5 and 10 μM As(III) for 1, 6, 12 
and 24 h. A concentration-dependent increase in gap formation and loss or non-uniform 
staining of VE-cadherin was observed with As(III) treatment at all time points, and the 
frequency and size of gaps observed were maximal at the 6-h time point. The cPKC 
inhibitor, Gö 6976, inhibited gap formation at all concentrations of As(III) treatment, and 
uniform distribution of VE-cadherin could be observed at cell-cell junctions. A similar 
concentration-dependent effect of As(III) was also observed on β-catenin distribution as 
analyzed at the 6-h time point. The frequency of gap formation was greater with 10 μM 
As(III) than with 1 and 5 μM As(III), and non-uniform distribution or loss of β-catenin 
staining was evident wherever gaps could be observed. Also, 250 nM Gö 6976 treatment 
inhibited the gap formation induced by 10 μM As(III) and restored the β-catenin staining 
at cell-cell junctions. 
 Analysis of the effect of As(III) treatment on VE-cadherin protein content at the 
24-h time point revealed approximately 8, 15 and 30% reductions in VE-cadherin protein 
with 1, 5 and 10 μM As(III) treatment, respectively. Protein content was analyzed by 
Western blotting. 
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 The cadherin/catenin complex associates with the actin cytoskeleton, which is 
crucial for maintaining junctional stability and structural integrity of the endothelial cell 
monolayer. Reorganization of actin microfilaments into stress fibers can adversely affect 
monolayer integrity, since it can lead to dissociation of the cadherin/catenin complex 
from the actin cytoskeleton. The effects of 1, 5 and 10 μM As(III) on reorganization of 
actin microfilaments were analyzed at 1, 6, 12 and 24 h by immunofluorescence staining 
using fluorophore-conjugated phalloidin. A concentration-dependent increase in stress 
fiber formation was observed with As(III) treatment at all time points, and the density of 
stress fibers observed was maximal at the 6-h time point. The cPKC inhibitor, Gö 6976, 
inhibited/reduced stress fiber formation at all concentrations of As(III) treatment.  
 As(III) treatment resulted in gap formation and stress fiber formation that was 
maximal at the 6-h time point. Hence, the effect of 1, 5 and 10 μM As(III) treatment on 
endothelial permeability was analyzed at the 6-h time point. A 5% increase in 
permeability was observed with 1 and 5 μM As(III) treatment, whereas 10 μM As(III) 
induced approximately a 19% increase. Treatment with 250 nM Gö 6976 inhibited the 
increase in permeability induced by 10 μM As(III).  
 Taken together, this study demonstrates that As(III) induces activation of PKCα 
without peroxynitrite formation in HAECs. No activation of PKCβ was observed at the 
time point analyzed. As(III)-induced activation of PKCα leads to tyrosine 
phosphorylation of β-catenin and formation of stress fibers. Tyrosine phosphorylation of 
β-catenin may cause weakening of the adherens junctions, and this effect, in association 
with the contractile force generated by stress fibers, results in gap formation and 
increased endothelial permeability. The intercellular gaps and increased permeability 
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caused by As(III) could potentially accelerate/enhance influx of oxLDLs and 
monocytes/macrophages across the endothelium and contribute significantly to the 
progression of atherosclerosis. Accordingly, environmentally relevant concentrations of 
arsenic induce significant increases in atherosclerotic plaque formation in the ApoE-/- 
/LDLr-/- mouse. The process of atherosclerosis is plausibly initiated or accelerated by 
arsenic at an early stage. The arsenic-induced, cPKC-dependent, signaling pathway 
mediating endothelial barrier disruption is outlined in Fig. 31. 
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Fig. 31. Schematic of arsenic mediated endothelial disruption and development of 
atherosclerosis 
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4.2 Future Directions 
The increase in vascular permeability with arsenic treatment has been 
demonstrated in vivo in rodents (Chen et al., 2004, Tsai et al., 2005). Visualization of 
stress fiber formation as well as cell retraction or gap formation after arsenic treatment in 
vivo will provide affirmation to the in vitro effects observed. Our study demonstrated 
PKCα mediated disruption of the endothelial monolayer. Arsenic is a versatile molecule 
and affects signaling pathways in multiple ways. The mechanism(s) of arsenic-induced 
activation of PKCα needs to be elucidated. PKC is a very important signaling molecule 
that has a host of cellular substrates and plays an important role in several physiological 
and pathological processes. Determining the specific substrate(s) of PKCα that mediates 
downstream tyrosine phosphorylation of adherens junction proteins and endothelial 
disruption will be crucial. This will help in designing specific pharmacological 
intervention strategies without affecting other physiological processes.  
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Chapter 5 
Role of Arsenic in Endothelial Cell Activation and Uptake of Modified 
Lipids by Macrophages 
 
5.1 Objective 
Atherosclerosis is an inflammatory disease, initiated by activation of the 
endothelium and characterized by expression of cell adhesion molecules and secretion of 
proinflammatory cytokines and chemokines. These events promote the transmigration of 
leukocytes into the subendothelial matrix, resulting in the growth of atheroma. The 
objective of this study was to determine whether arsenic induces endothelial cell 
activation and promotes uptake of modified lipids by macrophages, thereby mimicking 
the events of the initiation and progression of the atherosclerotic disease processes. 
 
5.2 Introduction 
Atherogenesis begins with the endothelial cells lining the vessel wall. Activated 
endothelial cells express cell adhesion molecules such as E-selectin, intercellular cell 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). E-
selectin is involved with the rolling and tethering of leukocytes to the activated 
endothelium, whereas ICAM-1 and VCAM-1 promote firm adhesion of leukocytes via 
interaction with the integrin molecules expressed on leukocytes (Blankenberg et al., 
2003). In particular, VCAM-1 and not ICAM-1 has been demonstrated to function 
primarily in monocyte recruitment to the blood vessel intima (Cybulsky et al., 2001). In 
addition to the cell adhesion molecules, proinflammatory cytokines such as interleukin-1 
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(IL-1), IL-6, macrophage colony-stimulating factor (M-CSF), granulocyte macrophage 
colony-stimulating factor (GM-CSF) and tumor necrosis factor α (TNFα) produced by 
various cell types such as endothelial cells, macrophages and smooth muscle cells play an 
important role in the atherosclerotic process (Tedgui and Mallat, 2006) by instigating a 
self-perpetuating inflammatory process.  
 The cytokine, M-CSF, stimulates the differentiation of monocytes into 
macrophages in the subendothelium as well as expression of macrophage scavenger 
receptors (Lusis, 2000). The uptake of modified low density lipoproteins (LDL) by 
resident macrophages is mediated by scavenger receptors. Class A scavenger receptor, 
SR-A, and class B scavenger receptor, CD36, are the two scavenger receptors of primary 
importance. It has been demonstrated that SR-A and CD36, together, are responsible for 
uptake of the majority of modified LDLs by macrophages (Kunjathoor et al., 2002). The 
uptake of these modified LDLs by resident macrophages leads to formation of lipid-laden 
macrophages known as foam cells. In vivo studies have demonstrated that mice lacking 
either of these scavenger receptors show a reduction in atherosclerotic lesions (Suzuki et 
al., 1997, Febbraio et al., 2000). 
 Conflicting results have been documented regarding the effects of arsenic on IL-6 
production. In vitro experiments suggest that high concentration of arsenic inhibits IL-6 
production (Hershko et al., 2002), whereas in vivo studies have demonstrated increased 
IL-6 production with arsenic treatment (Liu et al., 2000). Evidence showing a clear and 
direct relationship between arsenic exposure and expression of cell adhesion molecules, 
an indicator of endothelial activation, was lacking when our study was proposed. 
However, Tsou et al. (2005) have since shown that arsenic enhances TNFα-induced 
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expression of VCAM-1. The effect of arsenic on the uptake of modified lipids by 
macrophages also remains unknown. Therefore, the objective of this study was to 
determine whether arsenic modulates the process of atherosclerosis at an early stage 
using an in vitro cell system. 
 
5.3 Materials and Methods 
5.3.1 Cell culture. Human aortic endothelial cells (HAECs) were purchased from 
Cambrex Bio Science (Walkersville, MD) and were grown in the supplier’s formulated 
medium: EBM-2 medium supplemented with EGM-2 SingleQuots (0.04% 
hydrocortisone, 0.4% hFGF-B, 2% FBS and 0.1% each of VEGF, R3-IGF-1, ascorbic 
acid, heparin, hEGF and GA-1000). Bovine aortic endothelial cells (BAECs) were 
provided by Dr. J. Douglas Coffin of The University of Montana, Missoula and were 
originally a gift from Dr. Steve Schwartz of The University of Washington. Cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) with penicillin/streptomycin and 
L-glutamine, and supplemented with 15% FBS (Mediatech, Inc., Herndon, VA). 
Endothelial cells were used between passages 2 and 10. The human monocytes, THP-1 
cells, were a gift from Dr. Elizabeth Putnam of The University of Montana, Missoula and 
were grown in suspension in RPMI 1640 medium (Mediatech, Inc., Herndon, VA) 
containing 2 mM L-glutamine, 10 mM HEPES and 1.5 g/l sodium bicarbonate, and 
adjusted to contain 4.5 g/l glucose, 1.0 mM sodium pyruvate, 0.05 mM 2-
mercaptoethanol and 10% FBS (Mediatech, Inc., Herndon, VA). The mouse 
macrophages, RAW 264.7 cells, were a gift from Dr. Andrij Holian of The University of 
Montana, Missoula and were grown in DMEM with penicillin/streptomycin and L-
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glutamine, and supplemented with 10% FBS. Cells were incubated at 37 0C under a 
humidified atmosphere containing 5% CO2.  
 
5.3.2 Enzyme-linked immunosorbent assay. HAECs were seeded at a density of 
5x104 or 1x105 cells/well in 24-well plates for 24-48 h. Confluent cells were treated with 
1, 5 and 10 μM As(III) (GFS Chemicals, Columbus, OH) for 1, 6, 12, 24 and 48 h. After 
respective time points, medium containing As(III) was removed and cells were exposed 
to fresh medium without As(III) for 24 h. IL-6 released in the medium without As(III) 
was assayed by ELISA (BD biosciences, San Diego, CA) according to manufacturer’s 
instructions.  
 
5.3.3 Flow cytometric analysis of VCAM-1 expression. HAECs were seeded at a 
density of 1x106 cells/flask in 25 cm2 cell culture flasks for 48 h. Confluent cells were 
treated in serum free medium with 1, 5 and 10 μM As(III) for 24 h. Cells were 
trypsinized using trypsin (0.025%)/EDTA (0.01%) solution (Cambrex Bio Science, 
Walkersville, MD). This concentration of trypsin/EDTA has been shown not to affect the 
VCAM-1 protein during trypsinization (Zhang and Frei, 2002, van der Zijpp et al., 2003). 
Cells were collected by centrifugation and resuspended in phosphate buffered saline 
(PBS)/5% FBS solution. Cells were incubated with allophycocyanin (APC)-conjugated 
mouse anti-human VCAM-1 monoclonal antibody (concentration = 20 μl/106 cells) (BD 
Biosciences, San Diego, CA) for 45 min at 4 oC. Cells were then rinsed twice with PBS 
and fluorescence was analyzed using Becton Dickinson (BD) Facs Aria flow cytometer 
(San Jose, CA). A total of 10,000-30,000 viable cells were analyzed per experimental 
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sample. Data were analyzed using BD Facsdiva software. Background binding was 
detected using an APC-conjugated mouse IgG isotype control (BD Biosciences, San 
Diego, CA). 
 
5.3.4 Flow cytometric analysis of lipid uptake by macrophages. The effect of serum 
obtained from ApoE-/- /LDLr-/- mice on the uptake of acetylated LDL by RAW 264.7 
macrophage cells was analyzed by flow cytometry. Mice were obtained from Jackson 
Laboratories (Bar Harbor, ME). All the animals were housed under specific pathogen-
free conditions according to IACUC protocols with 12 h light/dark cycle and controlled 
temperature. ApoE-/- /LDLr-/- mice receiving arsenic treatment were given 1 or 10 ppm 
As(III) for 18 weeks ad libitum via drinking water. The control group received ddH2O. 
The mice were fed a commercial mouse chow diet. Blood was collected from these mice 
at the end of treatment periods and serum was obtained by centrifugation of the blood at 
1,600 rpm for 5 min at 4 0C and was stored at -80 0C. The treatment of mice with As(III) 
and blood collection was done by former graduate student in our laboratory for other 
experiments. A solution of 15% mouse serum was made with DMEM and 1 ml of this 
serum solution was exposed to 1x106 RAW 264.7 cells for 24 h at 37 oC. After 22 h of 
incubation, 1 μg/ml fluorescein isothiocyanate (FITC)-conjugated acetylated LDL 
(Molecular Probes, Inc. Eugene, OR) was added to each tube and incubated for 2 h at 37 
oC. Cells were rinsed with PBS and fluorescence was analyzed using the flow cytometer 
as mentioned above using appropriate controls.  
To determine the uptake of acetylated LDLs by RAW 264.7 cells exposed to 
conditioned medium from BAECs and the role of the scavenger receptor, SR-A, in LDL 
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uptake, BAECs were seeded at a density of 5x105 cells/well in 6-well plates for 24 h. 
Cells were treated with 10 μM As(III) for 48 h. Medium containing As(III) was removed 
after 48 h and cells were incubated with serum free medium without As(III) for 24 h. 
RAW 264.7 cells (1x106) were exposed to 1 ml of the BAEC conditioned medium 
without As(III) for 24 h at 37 0C. After 21 h of incubation, the SR-A blocking antibody, 
2F8 (8 μg/ml), was added wherever necessary and after 22 h, 1 μg/ml FITC-conjugated 
acetylated LDL was added to each tube. Cells were rinsed with PBS and fluorescence 
was analyzed using the flow cytometer as mentioned above using appropriate controls. 
To determine the effective concentration of 2F8 antibody in blocking SR-A, RAW 264.7 
cells were incubated with varying concentrations of 2F8 antibody for 45 min followed by 
incubation with 1 μg/ml FITC-conjugated acetylated LDL for 2 h at 37 0C. Cells were 
rinsed with PBS and acetylated LDL uptake was analyzed by flow cytometry. 
To determine the uptake of acetylated LDLs by THP-1 cells exposed to conditioned 
medium from HAECs, HAECs were seeded at a density of 1x106 cells/flask in 25 cm2 
cell culture flask for 48 h. Confluent cells were treated with 1, 5 and 10 μM As(III) for 24 
and 48 h. After respective time points, medium containing As(III) was removed and cells 
were exposed to fresh medium without As(III) for 24 h. Differentiated THP-1 cells 
(1x106) were exposed to 1 ml of the HAEC conditioned medium without As(III) for 24 h 
at 37 0C. THP-1 cells were differentiated using 33 μg/ml Phorbol 12-Myristate 13-
Acetate (PMA) (Sigma-Aldrich, Saint Louis, Missouri). After 22 h of incubation, 1 μg/ml 
FITC-conjugated acetylated LDL was added to each tube and incubated for 2 h. Cells 
were rinsed with PBS and acetylated LDL uptake was analyzed by flow cytometry. 
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5.3.5 Statistical analysis. Results are presented as mean ± standard error of the mean 
(SEM). When required, data was normalized with its respective control in order to 
exclude differences in background conditions. Statistical analysis was performed using 
Student’s t test when comparing two groups or Bonferroni method for comparing three 
groups or more. When using the Bonferroni method, the alpha level of each individual 
test was adjusted downwards to ensure that the overall experiment wise-risk remains at 
0.05. Statistical analysis was performed using GraphPad Prism, version 4.00. Alpha error 
was set at p<0.05. 
 
5.4 Results 
5.4.1 Effect of As(III) on endothelial VCAM-1 expression 
VCAM-1 mediates firm adhesion of leukocytes to the endothelium and transmigration 
into the blood vessel intima (Blankenberg et al., 2003, Cybulsky et al., 2001). Therefore, 
we analyzed the effect of As(III) on endothelial VCAM-1 expression by flow cytometry. 
HAECs were exposed to 1, 5 and 10 μM As(III) for 24 h. No change in VCAM-1 
expression was observed with As(III) treatment (Fig. 32).  
 
5.4.2 Effect of As(III) on IL-6 secretion 
The proinflammatory cytokine, IL-6, plays an important role in the development of 
atherosclerosis (Tedgui and Mallat, 2006). HAECs were exposed to 1, 5 and 10 μM 
As(III) for 1, 6, 12, 24 and 48 h. After the respective time points, As(III) containing 
medium was replaced with regular medium without As(III) for 24 h, and IL-6 levels were 
analyzed in medium without As(III) by ELISA. A concentration-dependent decrease in 
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IL-6 levels was observed with As(III) treatments compared to respective controls at most 
time points (Fig. 33).  
 
5.4.3 Acetylated LDL uptake by RAW 264.7 cells exposed to mouse serum 
Following transmigration of monocytes into the blood vessel intima, the monocytes are 
differentiated into macrophages and take up modified LDLs leading to formation of foam 
cells (Lusis, 2000). We therefore analyzed whether serum from As(III) treated mice could 
promote the uptake of acetylated LDLs by mouse macrophages, RAW 264.7 cells, using 
flow cytometry. Serum was obtained from mice treated with 1 and 10 ppm As(III) in 
drinking water for 18 weeks. Exposure of RAW 264.7 cells to serum from 1 ppm As(III) 
treated mice resulted in a significant increase in acetylated LDL uptake (Fig. 34A), 
whereas serum from 10 ppm As(III) treated mice showed an increasing trend (Fig. 34B). 
 
5.4.4 Acetylated LDL uptake by RAW 264.7 cells exposed to conditioned medium 
from As(III)-treated BAECs and the role of SR-A in LDL uptake. 
The role of the scavenger receptor, SR-A, expressed by RAW 264.7 cells in the uptake 
acetylated LDL was analyzed by treating cells with increasing concentration (1, 2, 4, 8 
and 10 μg/ml) of the SR-A blocking antibody, 2F8. A concentration-dependent decrease 
in acetylated LDL uptake was observed with increasing concentration of 2F8 antibody 
(Fig. 35A). In further experiments 8 μg/ml concentration of 2F8 antibody was used. 
To analyze the effect of As(III) on the uptake of acetylated LDLs by RAW 264.7 
cells, BAECs were exposed to 10 μM As(III) for 48 h, after which the As(III) containing 
medium was replaced with serum free medium without As(III) for 24 h. RAW 264.7 cells 
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were exposed to the conditioned medium from BAECs and an increasing trend in 
acetylated LDL uptake was observed (Fig. 35B). The acetylated LDL uptake was 
inhibited by pretreatment of RAW 264.7 cells with 2F8 antibody (Fig. 35B). 
 
5.4.5 Acetylated LDL uptake by THP-1 cells exposed to conditioned medium from 
As(III)-treated HAECs 
The effect of As(III) on acetylated LDL uptake was also analyzed using a human cell 
system. HAECs were exposed to 1, 5 and 10 μM As(III) for 24 and 48 h. After the 
respective time points, As(III) containing medium was replaced with regular medium 
without As(III) for 24 h, and uptake of acetylated LDLs by differentiated THP-1 cells 
was analyzed using the conditioned medium. At the 24-h time point, differentiated THP-1 
cells showed an increasing trend in acetylated LDL uptake with 5 μM As(III), whereas a 
decreasing trend was observed with 10 μM As(III) (Fig. 36A). At the 48-h time point, 
exposure of differentiated THP-1 cells to the conditioned medium showed an increasing 
trend in acetylated LDL uptake with 1 μM As(III), whereas a decreasing trend was 
observed with 10 μM As(III) (Fig. 36B). 
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5.5 Figures 
Fig. 32. Effect of As(III) on endothelial VCAM-1 expression 
 
 
 
Fig. 32. Effect of As(III) on endothelial VCAM-1 expression. Confluent HAECs were 
treated with 1, 5 and 10 μM As(III) for 24 h and VCAM-1 expression was analyzed by 
flow cytometry using an APC-conjugated anti-VCAM-1 antibody.  
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Fig. 33. Effect of As(III) on IL-6 secretion 
 
 
 
Fig. 33. Effect of As(III) on IL-6 secretion. Confluent HAECs were treated with 1, 5 and 
10 μM As(III) for 1, 6, 12, 24 and 48 h. After the respective time points, As(III) 
containing medium was replaced with medium without As(III) for 24 h. IL-6 levels were 
measured by ELISA in the medium without As(III). Treatment groups marked with 
asterisks were significantly different from the respective controls (*, p<0.05). The control 
(100%) is indicated by dotted line. Error bars represent mean ± SEM for n=3-5 
experiments. 
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Fig. 34. Acetylated LDL uptake by RAW 264.7 cells exposed to mouse serum 
A. 
 
B. 
 
 
Fig. 34. Acetylated LDL uptake by RAW 264.7 cells exposed to mouse serum. RAW 
264.7 cells were exposed to 15% serum from mice treated with 1 ppm (A) and 10 ppm 
(B) As(III) for 18 weeks. Treatment group marked with asterisk was significantly 
different from the control (*, p<0.05). Error bars represent mean ± SEM for (A) n=8 
mice, (B) n=5 mice per group.  
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Fig. 35. Acetylated LDL uptake by RAW 264.7 cells exposed to conditioned medium 
from As(III)-treated BAECs and the role of SR-A in LDL uptake 
 
A. 
 
B. 
 
Fig. 35. Acetylated LDL uptake by RAW 264.7 cells exposed to conditioned medium 
from As(III)-treated BAECs and the role of SR-A in LDL uptake. The concentration-
dependent inhibition of acetylated LDL uptake by RAW 264.7 cells was analyzed using 
the 2F8 antibody, n=1 (A). BAECs were treated with 10 μM As(III) for 48 h and As(III) 
containing medium was replaced with medium without As(III) for 24 h. Acetylated LDL 
uptake by RAW 264.7 cells was analyzed using the conditioned medium (B). The control 
(100%) is indicated by dotted line in (B). Error bars represent mean ± SEM for n=3-4 
experiments. Treatment group marked with * and # was significantly different from the 
control and As(III) treated group, respectively, with p<0.001. 
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Fig. 36. Acetylated LDL uptake by THP-1 cells exposed to conditioned medium 
from As(III)-treated HAECs 
 
A. 
 
 
B. 
 
 
Fig. 36. Acetylated LDL uptake by THP-1 cells exposed to conditioned medium from 
As(III)-treated HAECs. Confluent HAECs were treated with 1, 5 and 10 μM As(III) for 
24 and 48 h. After the respective time points, As(III) containing medium was replaced 
with medium without As(III) for 24 h. Acetylated LDL uptake by differentiated THP-1 
cells was analyzed using the conditioned medium at the 24-h time point (A) and 48-h 
time point (B). The control (100%) is indicated by dotted line in (A and B). Error bars 
represent mean ± SEM for n=3 experiments. 
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5.6 Discussion 
Arsenic has been associated with the development of atherosclerosis in 
epidemiological and animal studies (Bunderson et al., 2004, Simeonova et al., 2003, 
Wang et al., 2002). In vitro studies have suggested several possible mechanisms for the 
development of cardiovascular diseases such as atherosclerosis (Navas-Acien et al., 
2005). We therefore investigated whether arsenic induces endothelial cell activation and 
promotes uptake of modified lipids by macrophages, thereby mimicking the events in the 
initiation and progression of the atherosclerotic disease processes. The results of this 
study suggest that As(III) alone does not induce the expression of the cell adhesion 
molecule, VCAM-1, or proinflammatiry cytokine, IL-6, in HAECs. Also, no clear 
evidence was obtained regarding the effects of As(III) on uptake of modified lipids by 
macrophages. 
 The VCAM-1 gene is regulated by multiple transcription factors such as nuclear 
factor-kappa B (NF-κB), activator protein-1 (AP-1), interferon regulatory factor-1 (IRF-
1) and Sp-1 (Lechleitner et al., 1998, Neish et al., 1995, Neish et al., 1992, Tsou et al., 
2005). Similarly, the IL-6 gene is regulated by multiple transcription factors such as NF-
κB, AP-1, C/EBP and CREB (Hershko et al., 2002). NF-κB is considered to be most 
important in the regulation of VCAM-1 and IL-6 expression. In vitro studies suggest that 
low levels of As(III) (1-5 μM) activate NF-κB (Barchowsky et al., 1996), whereas high 
As(III) levels (500 μM) inihibit NF-κB activation (Roussel and Barchowsky, 2000, 
Hershko et al., 2002). Consistent with this, Hershko et al. (2002) demonstrated that 500 
μM As(III) treatment inhibits IL-1β-induced IL-6 expression in enterocytes. Although in 
theory the As(III) concentrations used in the present study should activate NF-κB and 
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induce IL-6 production, no such outcome was observed. In vivo studies using mouse 
models, however, suggest that arsenic exposure increases serum IL-6 levels (Liu et al., 
2000, Chapter 2 of this dissertation). Also, in our study no VCAM-1 expression was 
observed with As(III) treatment. A similar effect of 10 μM As(III) on VCAM-1 
expression was documented by Tsou et al. (2005), where As(III) treatment alone did not 
induce VCAM-1 expression, but potentiated TNFα-induced VCAM-1 expression. This 
suggests that As(III) by itself does not induce cell adhesion molecule expression, but in 
the presence of other inflammatory cues may enhance the process. Simeonova et al. 
(2003) have demonstrated increased IL-8 mRNA levels with 5 μM As(III) treatment in 
HAECs. Therefore, it may be possible that arsenic treatment alone may induce only 
certain inflammatory mediators and exacerbate the effect of others. 
 Exposure of RAW 264.7 macrophages to conditioned medium from BAECs 
showed only a modest increasing trend in acetylated LDL uptake with As(III) treatment. 
The majority of the uptake was mediated by SR-A, which is in sync with other studies 
(Kunjathoor et al., 2002). Also, no specific effect in acetylated LDL uptake with As(III) 
treatment was observed using the THP-1/HAEC cell system. However, a significant 
increase in acetylated LDL uptake was observed with serum from 1 ppm As(III)-treated 
mice. This suggests that in vivo inflammatory conditions may influence the uptake of 
modified lipids that may not be possible to replicate in vitro. Exposure of macrophages to 
serum from 10 ppm As(III)-treated mice revealed only an increasing trend in acetylated 
LDL uptake. The reason for this finding is unclear.  
 The process of atherosclerosis is regulated by different inflammatory mediators 
secreted by several different cell types such as endothelial cells, leukocytes and smooth 
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muscle cells. Inflammatory mediators such as cytokines regulate the activity of cells in an 
autocrine or paracrine fashion and can trigger several different cellular responses 
depending on the timing and context. For example, the expression of cell adhesion 
molecules by endothelial cells is regulated by cytokines such as IL-6, IL-1β and TNFα 
(McDouall et al., 2001, Watson et al., 1996) that are secreted by macrophages, smooth 
muscle cells and/or endothelial cells, simultaneously or in unique temporal and spatial 
context. Consistent with this, it has been shown that 5 μM As(III) treatment induces IL-6 
and monocyte chemoattractant protein-1 (MCP-1) expression in human smooth muscle 
cells (Lee et al., 2005). Therefore, stimulatory signals to the endothelial cells from other 
cell types such as smooth muscle cells could be crucial. This makes it difficult to mimic 
in vivo atherosclerotic conditions in in vitro settings. Endothelial and smooth muscle cells 
in the vasculature along with resident macrophages play significant roles in the process of 
atherosclerosis. Therefore, co-culture experiments may more adequately reflect in vivo 
conditions during atherogenesis. In summary, arsenic did not increase the expression of 
VCAM-1 and IL-6 by itself, and the effects of arsenic on the uptake of modified lipids 
remain unclear in our experimental setting. 
 177
 
5.7 References 
1. Barchowsky, A., Dudek, E.J., Treadwell, M.D., Wetterhahn, K.E., 1996. 
Arsenic induces oxidant stress and NF-κB activation in cultured aortic 
endothelial cells. Free Radic. Biol. Med. 21(6), 783-790. 
2. Blankenberg, S., Barbaux, S., Tiret, L., 2003. Adhesion molecules and 
atherosclerosis. Atherosclerosis. 170, 191-203. 
3. Bunderson, M., Brooks, D.M., Walker, D.L., Rosenfeld, M.E., Coffin, D.J., 
Beall, H.D., 2004. Arsenic exposure exacerbates atherosclerotic plaque 
formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol. 
Appl. Pharmacol. 201, 32-39. 
4. Cybulsky, M.I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., 
Gutierrez-Ramos, J-C., Connelly, P.W., Milstone, D.S., 2001. A major role 
for VCAM-1 but not ICAM-1 in early atherosclerosis. J. Clin. Invest. 107, 
1255-1262. 
5. Febbraio, M., Podrez, E.A., Smith, J.D., Hajjar, D.P., Hazen, S.L., Hoff, H.F., 
Sharma, K., Silverstein, R.L., 2000. Targeted disruption of the class B 
scavenger receptor CD36 protects against atherosclerosis lesion development 
in mice. J.Clin.Invest. 105, 1049-1056. 
6. Hershko, D.D., Robb, B.W., Hungness, E.S., Luo, G., Guo, X., Hasselgren, P., 
2002. Arsenite inhibits interleukin-6 production in human intestinal epithelial 
cells by down-regulating nuclear factor-κB activity. Clin. Sci. 103, 381-390. 
7. Kunjathoor, V.V., Febbraio, M., podrez, E.A., Moore, K.J., Andersson, L., 
Koehn, S., Rhee, J.S., Silverstein, R., Hoff, H.F., Freeman, M.W., 2002. 
 178
 
Scavenger receptors class A-I/II and CD36 are the principal receptors 
responsible for the uptake of midified low density lipoprotein leading to lipid 
loading in macrophages. J. Biol. Chem. 277(49), 982-88. 
8. Lechleitner, S., Gille, J., Johnson, D.R., Petzelbauer., 1998. Interferon 
enhances tumor necrosis factor-induced vascular adhesion molecule 1 
(CD106) expression in human endothelial cells by an interferon-related factor 
1-dependent pathway. J. Exp. Med. 187(12), 2023-2030. 
9. Lee, P-C., Ho, I-C., Lee, T-C., 2005. Oxidative stress mediates sodium 
arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant 
protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol. Sci. 85, 
541-550. 
10. Liu, J., Liu, Y., Goyer, R.A., Achanzar, W., Waalkes, M.P., 2000. 
Metallothionein-I/II null mice are more sensitive than wild-type mice to the 
hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic 
arsenicals. Toxicol. Sci. 55(2), 460-467. 
11. Lusis, A.J., 2000. Atherosclerosis. Nature. 407, 233-241. 
12. McDouall, R.M., Farrar, M.W., Khan, S., Yacoub, M.H., Allen, S.P., 2001. 
Unique sensitivities to cytokine regulated expression of adhesion molecule in 
human heart-derived endothelial cells. Endothelium. 8(1), 25-40. 
13. Navas-Acien, A., Sharrett, A.R., Silbergeld, E.K., Schwartz, B.S., Nachman, 
K.E., Burke, T.A., Guallar, E., 2005. Arsenic exposure and cardiovascular 
disease: A systematic review of epidemiologic evidence. Am. J. Epidemiol. 
162(11), 1037-1049. 
 179
 
14. Neish, A.S., Read, M.A., Thanos, D., Pine, R., Maniatis, T., Collins, T., 1995. 
Endothelial Interferon Regulatory Factor 1 cooperates with NF-κB as a 
transcriptional activator of vascular cell adhesion molecule 1. Mol. Cell. Biol. 
15(5), 2558-2569. 
15. Neish, A.S., Williams, A.J., Palmer, H.J., Whitley, M.Z., Collins, T., 1992. 
Functional analysis of the human vascular cell adhesion molecule 1 promoter. 
J. Exp. Med. 176, 1583-1593. 
16. Roussel, R.R., Barchowsky, A., 2000. Arsenic inhibits NF-κB-mediated gene 
transcription by blocking IκB kinase activity and IκBα phosphorylation and 
degradation. Arch. Biochem. Biophys. 377(1), 204-212. 
17. Simeonova, P.P., Hulderman, T., Harki, D., Luster, M.I., 2003. Arsenic 
exposure accelerates atherogenesis in apolipoprotein E-/- mice. Environ. 
Health Perspect. 111, 1744-1748. 
18. Suzuki, H., Kurihara, Y., Takeya, M., Kamada, N., Kataoka, M., Jishage, K., 
Ueda, O., Sakaguchi, H., Higashi, T., Suzuki, T., Takashima, Y., Kawabe, Y., 
Cynshi, O., Wada, Y., Honda, M., Kurihara, H., Aburatani, H., Doi, T., 
Matsumoto, A., Azuma, S., Noda, T., Toyoda, Y., Itakura, H., Yazaki, Y., 
Horiuchi, S., Takahashi, K., Kruijt, J.K., van Berkel, T.J.C., Steinbrecher, 
U.P., Ishibashi, S., Maeda, N., Gordon, S., Kodama, T., 1997. A role for 
macrophage scavenger receptors in atherosclerosis and susceptibility to 
infection. Nature. 386, 292-296.  
19. Tedgui, A., Mallat, Z., 2006. Cytokines in atherosclerosis: Pathogenic and 
regulatory pathways. Physiol. Rev. 86, 515-581. 
 180
 
20. Tsou, T-C., Yeh, S-C., Tsai, E-M., Tsai, F-Y., Chao, H-R., Chang, L-W., 
2005. Arsenite enhances tumor necrosis factor-α-induced expression of 
vascular cell adhesion molecule-1. Toxicol. Appl. Pharmacol. 209, 10-18. 
21. van der Zijpp, Y.J.T., Poot, A.A., Feijen, J., 2003. ICAM-1 and VCAM-1 
expression by endothelial cells grown on fibronectin-coated TCPS and PS. J. 
Biomed. Mater. Res. 65A, 51-59. 
22. Wang, C.H., Jeng, J.S., Yip, P.K., Chen, C.L., Hsu, L.I., Hsueh, Y.M., Chiou, 
H.Y., Wu, M.M., Chen, C.J., 2002. Biological gradient between long-term 
arsenic exposure and carotid atherosclerosis. Circulation 105(15), 1804-1809. 
23. Watson, C., Whittaker, S., Smith, N., Vora, A.J., Dumonde, D.C., Brown, 
K.A., 1996. IL-6 acts on endothelial cells to preferentially increase their 
adherence for lymphocytes. Clin. Exp. Immunol. 105, 112-119. 
24. Zhang, W-J., Frei, B., 2002. Albumin selectively inhibits TNFα-induced 
expression of vascular cell adhesion molecule-1 in human aortic endothelial 
cells. Circ. Res. 55, 820-829. 
 181
